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Introduction 

Molecular complexity of the cell  
The classical paradigm of the cell 
The cell is the unit of function, structure and phenotype in living systems1.  Since its 
first observation by Hooke in 1665 2, and then it’s characterization in 1824 as the 
“fundamental element of organization”  in an organism 3, the understanding of its 
complexity has evolved a great deal. In fact, the understanding of its complexity has 
progressed from being a “bag of enzymes” to a highly organized complex network of 
molecules4. The post-Mendelian theory was the dominant model to describe the 
phenotype behavior of the cell for over 100 years. This theoretical framework features 
a one-to-one correspondence of one gene to one function. Evidence for this one-to-
one relationship was supported in 1923 based on causal alterations in one single 
protein, an enzyme of tyrosine metabolism, on the inherited disease alcaptonuria, 
published by Archibald Garrod 5. What followed in the succeeding years was the 
“one-gene-one-enzyme” theory, a term coined in 1945 by Horrowitz 6. His work, and 
that of his collaborators, Beadle and Tatum, on inherited defects in the mold 
Nueorsposa crassa 7, laid down the foundation for this long held concept that has 
served to explain cellular behavior for several succeeding decades.  
Complexity & emergent properties of the cell 
This once steadfast paradigm of one gene one protein functions has been replaced by 
the acceptance that the cell’s molecules operate in a much more complex system of 
inter-dependent relationships. This system is governed by “non-linear” dynamics with 
emergent properties, i.e. the whole is greater than the sum of its isolated parts. This 
has become apparent in recent years through the many revelations brought to the fore 
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by the advent of high-throughput –omics technologies. For example, genome-wide 
associations studies (GWAS) has shown that much of the heritability of complex 
traits is apparently unexplained by initial GWAS, and this “hidden” component of 
complex disease still cannot be traced 8. Historically, some have postulated that the 
number of possible molecular components in cellular organism is a determinant of 
complexity. In the case of genes for example, in 1964 Friedrich Vogel made a 
preliminary estimate of 6.7 million genes in the human genome9. He based this 
estimate on the accurate knowledge of the time, in addition to wildly incorrect 
assumptions that seemed justified at the time (such as all DNA being coding, and the 
average size of proteins). From the considerable volume of evidence accumulated in 
the subsequent years, we now estimate the number of genes in human approximately 
to be around 22,33310, even lower than the 27,000 genes in the plant and model 
organism Arabidopsis thaliana11 (hale cress). Thus the number of molecular 
components in the cell of an organism has little relation to complexity and expression 
of phenotype behavior.  
A network perspective of the cell 
It could be argued that currently there is no solid theoretical framework that can 
effectively model the complex system of the cell, and how its large numbers of 
dimensions interact in a non-linear manner to produce a phenotype.  However, that 
which has become transparent through the identification of the molecular components 
of the cell on the “–omics”, or attempted comprehensive, scale, is the large network of 
molecular interactions, of various types, that occur within the cell12. Each of these 
networks could be considered to be subsystems of larger systems. These different 
systems of complex networks cooperate with each other, in a manner we do not fully 
understand, to manifest the phenotype of the cell.  
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The promise of computational and integrated bioinformatics approaches may help to 
build an accurate map of these interactions and to elucidate their mechanisms of 
function. This will at least lead to a better comprehension of complex cellular 
behavior.  One widely used and rapidly evolving toolkit that can help us explore the 
dynamics and mechanisms of cellular complexity is the rapidly progressing field of 
network biology.
  )
Molecular networks of the cell 
Network interpretation of molecular interactions 
Molecular cellular networks are the maps of the known components in a cell. These 
components include amino acids, nucleic acids, lipids, metabolites and metal 
compounds. They form a complex web of interactions that regulate biochemical 
homeostasis and determine the dynamic cellular response to external stimuli. High-
throughput “–omics” technologies have been progressing rapidly in recent years to 
detect large sets of these molecular components 12. Representation and analysis of 
cellular constituents through network principles is a promising and a popular 
analytical approach towards a deeper understanding of molecular mechanisms in a 
system-wide context 13,14. The building and then deciphering of function from protein 
signaling networks also has great potential to aid discovery of new therapeutic 
intervention15.  
We can conceptually delineate three main classes of molecular cellular network being 
studied: metabolic, regulatory and signaling. Each of these classes of molecular 
networks represents physical binding interactions between molecular cellular 
components. These can be seen as somewhat conceptual classifications, as in reality 
these networks and their components work in an integrated fashion to respond to 
stimuli and confer the behavior of the cell.  
Metabolic networks 
Metabolic networks chart the interactions between all biochemical species in a cell4,16. 
In this class of molecular networks, the nodes are metabolites of chemical reactions in 
the cells, and the edges represent a description of the chemical reactions or enzymatic 
functions that alters the metabolite4. Although classic human metabolic pathways, 
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such as glycolysis and the urea cycle, have been studied for almost a hundred years, a 
complete human metabolic network does not exist. Limited maps in human of 
metabolic networks have been developed17-20 and more extensive maps in prokaryotes 
are also in existence 18. Some of these metabolic networks have been studied 
computationally in network models and simulations 21,22. However, harnessing 
complete maps requires complete genomic knowledge and the complete acquisition of 
the functional relationships of all enzymatic proteins and metabolites. Although we 
fall significantly short of comprehensive knowledge of this biochemically-detailed 
class of network, there are interesting developments to construct and model metabolic 
networks. In human liver cells, for example, a genomic reconstruction of metabolic 
networks discerned metabolic states in at a large variety of physiological conditions23. 
The organization of metabolic networks have been shown to correspond to chemical 
properties which appear sensible for this organization24. The importance of the 
interplay between these small metabolites in regulating the activity of protein 
functions, through their integration with protein networks, has been reported 
recently25. Critical functions can now be placed on the metabolite-protein network, 
implicating the pathogenesis of many diseases and mechanistic action of various 
potential new drugs. This warrants future network studies of these biochemically-
detailed networks, not in isolation, but as integrated cellular systems.  
Gene regulatory networks 
Gene regulatory networks (GRNs) are a class of molecular networks that are 
composed of transcriptional networks of gene regulation. In this class of molecular 
networks, nodes are protein transcription factors or a DNA regulatory sequence and 
the edges are directed to the binding of the transcription factor to the regulatory 
sequence. These networks are complex control systems that regulate the expression of 
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thousands of genes in any given process in life and are particularly important during 
the formation of life during development 
26
.  In recent years, there has been rapid 
developments to capture these relationships on a large scale in different organisms, 
namely the yeast one hybrid (Y1H) system 
27,28
, chromatin based ChiP-Seq
29
 and 
ChiP-chip arrays
30
. Various computational models using networks have been 
developed and applied in recent years to analyze GRNs 
31,32
. These methods range 
from the very first application of qualitative Boolean (logic based) networks in 1969 
by Kaufmann
33
, to continuous models that incorporate more dynamic and quantitative 
behavior of the gene expression using differential equations 
33
. Incomplete knowledge 
and a mechanistic understanding of how gene regulation is governed in the cell limits 
the accurate modeling of GRNs. For example, there is increasing importance 
attributed to the role of micro RNAs (miRNAs) to regulate the mRNA expression 
levels in a cell
34
.  For example, miRNAs are integral to the differentiation of 
monocytes, governing the expression of key protein networks that modulate this 
process
35
. The experimental strategies to capture this information are only now 
progressing on a large scale
34,36
, and as a result a lot of these relationships are limited 
to computationally predicted targets of the miRNAs. Furthermore, the concept held 
for over 50 years of how a gene is regulated in a GRN, that of the Jacob/Monod 
lactose-operon explanation of a bacterial gene regulation circuit
37
, is now known to be 
a much more integrated system involving the rich complexity of the entire cell
38
. 
Inherent in all aspects of GRNs are interconnected protein networks, involving 
interacting protein complexes or cellular machines, packaging the genome and 
organizing it in the nucleus
39
 . This interaction network brings about a 3D 
conformation and compartmentalization compatible for a specific transcription factor 
program to render its gene expression program in the cell. Therefore, to truly 
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understand how gene expression is governed, we must capture complete information 
of the DNA and RNA regulatory elements that are integrated with protein networks in 
the cell to provide a platform for the cell to respond to stimuli and express its 
phenotype.  
Protein networks  
The third class, and the primary focus of this study, is that of protein networks. The 
underlying basis of these molecular networks consists of binary protein interactions. 
In these networks, the nodes represent proteins and the edges represent physical 
binding interactions between two proteins. These are also commonly phrased in the 
literature as protein-protein interactions or PPI networks. The classical and once 
dominant model for protein signaling networks is that of a canonical “pathway”. This 
is a one-dimensional cascade consisting of tens of proteins, hierarchically organized, 
and independent from the rest of the protein network of the cell. The pathway model 
has been useful as a tool to explain the properties of some cellular functions, and 
pathways have been catalogued in many useful databases 18,40,41. However, the 
pathway paradigm is a limited and linear conceptual framework to understand both 
normal and disease cellular behavior. Their limitedness in scope and coverage across 
the many interconnected cellular processes resulting in them missing many important 
interacting protein pairs, make these resources inconistent42. New models and 
analyses of large-scale protein networks are evolving to respond to emerging high-
throughput technologies that allow for a very alternative view of signal 
transduction43,44.  It is increasingly apparent that these large-scale screens and their 
accompanying network analyses are taking precedence to study cell signaling44. The 
acquisition and analysis of protein interactions is critical to gain a systems level 
understanding of the cellular complexity45,46 
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Protein networks & crosstalk mechanisms 
The study of the cell and its relationship to diseases such as cancer is likely to benefit 
a great deal from a global network understanding of how information signals are 
propagated in the cell. Such a global network view of the cell can facilitate important 
studies that characterize crosstalk in protein signals in disease states, like for example 
that of the EGFR and insulin receptor pathways47 or between CDK8 of the mediator 
complex and β-catenin activity in colorectal cancer48. Crosstalk mechanisms have not 
been studied as thoroughly as linear signaling pathways, and network biology is 
opening up to their discovery and characterization49. Characterizing crosstalk signals 
in molecular networks will be crucial to understand pathogenesis, particularly so in 
cancer50 and the immune system 49. In many cases, this will lead to beneficial clinical 
outcome. For example, a protein network approach has recently lead to an improved 
understanding of the resistance of melanoma cells to the BRAF kinase inhibitors, 
demonstrating the importance of pathway crosstalk signaling in drug inhibition51 
Biochemical modifications in protein networks 
The complex phenotype of a cell may also be seen as a function of the different 
biochemical states a protein may be in, and also as the complex network of 
interactions between the species these states create. Protein networks, in the true 
reality of the living cell, are not the static structures as we see them corresponding to 
function. Rather, protein networks exist as cooperative systems, communicating 
through various different biochemical mechanisms to propagate signals. These are 
collectively termed post-translational modifications, such as phosphorylation and 
ubiqutination. In many cases, they effectively confer a different species of function 
onto a protein that will then determine its fate and pattern of further interactions. 
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These chemical modifications to proteins are also being populated into various 
databases52-54 and are increasingly used in network models. There are studies that have 
achieved positive results in using protein networks to predict phophorylation sites, an 
improvement on the standard sequence based predictions for these sites55,56.  Another 
study has manually curated ubiquitin posttranslational modifications (PTM) on to 
binary interactome data and has computationally identified high-confidence 
interaction signals57. For the most part, this level of information is absent in network 
analysis and large-scale screens and their accompanying networks approaches, 
because of the sparse amount of experimental verification of sites of PTMs. This is 
the main current drawback on using large-scale protein networks approaches 
compared to the canonical pathway model. Although adding additional layers of 
complexity, as this information is populated into rapidly growing databases or 
harnessed through advancing proteomics approaches58,59, applied to specific cellular 
processes such as phosphorylation during mitosis58 or apoptosis60. The integration of 
these upcoming resources and their analysis in protein networks will be a powerful 
area of future cellular network biology research.
  
The acquisition and analysis of protein networks  
Community efforts to organize & structure protein networks 
To gain an understanding of the complex processes occurring in the cell through its 
protein networks, it is crucial that all protein interactions are eventually identified and 
adequately organized.  It is estimated that most of the binary protein interactions in 
the human protein network remain experimentally undiscovered 61.  There have been 
many efforts in recent years to experimentally harvest these protein interactions using 
high-throughput experimental procedures in human62-64 and many model organisms, 
such as yeast 65-67. There are ongoing research efforts to improve the quality of these 
binary interactions to produce high-confidence connections 61,68. Efforts to study the 
quality of interaction networks have reported extensive incompleteness and noise69,70. 
Independent efforts are progressing continuously to build comprehensive protein 
network databases71-79. With the growing number of protein interactions being 
catalogued, it is essential to use organized relationships of interactions in a 
consolidated and non-redundant manner80. Important community efforts are underway 
to achieve this 81-83 and their results will be central to any application to study the 
protein complexity of cells. 
Data mining for protein networks 
Although protein interaction information resources are continuously expanding, they 
are still very much incomplete 61,84. For that reason, prediction methods hold great 
importance to acquire a more complete perspective of cellular complexity and to infer 
various biological relationships of complex phenotypes. One common strategy to 
predict protein interactions is to use the conserved sequences, or functional domain 
sequences of known protein interactions, i.e. their binding interfaces, to infer putative 
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interactions 85-105. These sequence and protein domain family methods have resulted in 
various levels of success. Another approach is to use the genome features of protein 
pairs to predict interactions. One such experimentally validated effort to 
computationally predict interactions has demonstrated that using a Bayesian analysis 
applied to genomic features is very promising in discovering novel protein 
interactions106. The STRING database integrates multiple sequence, literature and 
experimental parameters to predict interactions107, and its comprehensiveness has 
made it a popular source for protein interactions.  
Text-mining for protein networks 
An alternative approach to capture the enormous scale of protein interactions in the 
cell is to use automatic extraction of these relationships, from the ever-expanding 20 
million-plus articles in Medline 108. Indeed, in general terms literature mining has now 
distinguished itself as a viable method to capture and organize many types of 
biologically relevant information 109-111.  With respect to protein networks, literature 
mining approaches have been used for over 10 years to extract protein interactions 
from the Medline database. First, based on the simple rules of co-occurrence of two 
proteins mentions in an article’s abstract112,113, and later progressed to more elaborate 
procedures that incorporate machine learning 114,115, Bayesian inference116, 
linguistic117,118 and ontology 119,120 based approaches.  Both these automated literature 
mining methods, and the time consuming process of manually reading and curating 
the literature for protein interactions121, are both error prone and replete with biases. 
One of the most often highlighted biases is their containing more interactions for 
well-studied biomedical concepts61,121. 
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Boolean modeling of protein networks 
All control of the molecular components in gene regulatory, protein, and metabolic 
networks are governed by a variety of biochemical mechanisms, with inputs from 
other network components that act additively or synergistically on the molecule in 
question. At present, most knowledge we have about protein networks is mainly 
qualitative in nature. Because our existing knowledge of complex protein networks is 
based on discrete qualitative values, Boolean models are appropriate models to 
analyze their behavior. Boolean networks, as applied to signaling in protein networks, 
are based on the assumption that binary “on” or “off” states functioning in discrete 
time steps and describe important aspects of outcome of the network. They have 
traditionally being used in the modeling of GRNs. The simplest dynamic models 
applied were developed for small random networks of transcriptional regulation in the 
1960's by Stuart Kauffman122,123.  Boolean networks have been limited to small 
networks in the past as a given network of n genes or proteins, there are a total there 
are 2n possible different phenotype states. This makes the updating of all possible 
states in real cellular networks inexorably large, and difficult to model in reality. The 
succession of states with time is monitored and a record is kept of which states are 
reached at each update. Some states may never be reached. The goal is find attractors: 
these are states or series of states that once reached, remain stable. The attractors can 
be synonymous with phenotype behavior of a cell as measured through 
experimentation, such as a gene expression outcome or a signature cytokine released 
by the cell in question. Kaufman considered each attractor as a stable differentiated 
state of the cell in 1969 when he first devised the approach123. In later years, he 
demonstrated that the number of differentiated cell types predicted by this model 
corresponds well with the current experimental knowledge124. The majority of studies 
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applying Boolean approach have dealt with GRNs, most of which were small in size 
(ca. 10 nodes). They have however begun to be used for logical analyses of signaling 
networks. One of the earliest examples of this trend was in 1999, using a small 
simplistic Boolean model governing the signal transduction of effector T-cell 
activation was formulated125.  
Alternative logic models to analyze protein networks 
In many cases the relationships in protein networks are too complex to be captured 
with simple Boolean logic, and therefore more general models have been developed. 
These models are still discrete model types, in addition to the types of networks 
previously analyzed Boolean networks, are so-called logical models126, Petri nets127 
and agent-based models128. It is possible that these approaches could be better 
performing solutions to elucidate the cellular mechanisms in complex molecular 
networks, such as that of T helper cell differentiation.  
Structural properties of cellular protein networks 
The application of network theory to cell biology has fundamentally altered our 
understanding and appreciation of the complexity of the cell4,129-131. There is no formal 
definition of the complexity of a cell, but networks provide us with an adequate set of 
tools to explore the relationships between the extraordinary high numbers of 
molecular components in the cell. The advent of these tools and network discoveries 
in recent years has provided the field of network biology with significant 
advancements. It has been observed, for example, that the topological properties 
distinguish real cellular networks from random networks4,132. Some of the topological 
properties have received very noticeable attention in the literature in the past decade. 
For example, the distribution of degree (the number of interactions per protein) in 
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cellular networks is often claimed to follow a power-law distribution4,133. This 
property of protein networks and metabolic networks has been found in all organisms 
where data exists, from yeast to human134. This, and its correlated features in protein 
networks arise important biological questions, the solutions to which may help to 
unravel the complexity of cellular networks and lead us to a perception of the 
functional organization.  
Tools for Network visualization 
Extracting relevant information from this huge amount of data becoming available for 
cellular network analysis requires dedicated tools. Such analysis of visual, topological 
and dynamic properties of cellular networks is a highly active area of research and 
development. Several very effective tools have been developed to address the need for 
network analysis. Some of these focus on the simple visualization aspects for data 
exploration and integration tasks135-140.  Other tools have been developed to offer more 
sophisticated analysis pipelines for integrating multiple datasets, for cluster analysis 
and to investigate the topological features of the network.136,140-142. Other tools have 
been developed for the dynamic analysis and implementation of systems biology 
models143. The recent rapid advanced in these tools have allowed typically large 
networks comprising several thousands of proteins and their interactions to be 
analyzed, efficiently and seamlessly. 
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Protein networks & Disease 
Inter-connectivity of protein networks in disease  
Network approaches offer an improved understanding of the relationship between the 
genes implicated in diseases 15,144-147 and may be a valuable resource to find candidate 
disease genes148. It has been reported that the Mendelian component of complex 
diseases, such as for example breast cancer, represent less than 30% of its incidence 
149
. In the particular case of breast cancer and the BRCA1 and BRCA2 genes, it is a 
mere 5% of all cases149. Furthermore, the recent results of the many GWAS 
undertaken in recent years have shown that a large amount of disease-causing genes 
are yet to be accounted for 8. To explain the missing causal factors of complex 
disease, it is suggested future investigations should focus not on the genes in and of 
themselves, but rather on the effect of the interaction of their protein products and 
perturbation of the cells protein networks 14,145,146. For diseases of simple Mendelian 
inheritance, it is suggested from their expression patterns that they have central 
importance in protein networks 150. In contrast to those arguments, the majority of 
Mendelian disease genes show no tendency to have high connectivity in protein 
networks, and their expression pattern indicate that they are localized in the functional 
peripheries of the network130,151. This makes sense in the light of most highly 
connected protein being those of essential genes130,151, and therefore their mutations 
would be deleterious during fetal development. Looking at these disease causing 
mutations from a protein structure perspective suggests that approximately 4% of 
single-gene disease mutations have an effect on the binding interfaces between 
protein interacting pairs152. Interestingly, there is a high level of disease gene 
clustering in protein networks151  detected, despite our current very limited knowledge 
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of protein networks84,153. This high degree of clustering of disease proteins in networks 
of the cell is the key element to future discovery and research of disease causing 
factors. The interconnectedness of disease proteins in communities or modules of 
interacting proteins may well be a source of the pathogenic phenotype. These disease 
proteins with high clustering possibly correspond with functional modules or protein 
complexes that are important to normal cellular function. This local clustering is 
important, as interactors of the disease gene, and not necessarily the disease gene 
itself, has important biochemical implications on a cellular process154. It is therefore 
proposed that in concert with genetic variation, protein interactions and the networks 
in which they operate are central to the pathogenesis of complex diseases and 
therefore a fruitful source of future disease gene discovery. This is shown to be 
increasingly the trend in light of the capturing of disease-associated protein network 
modules in large-scale screens of protein networks, in complex diseases ranging from 
autism 155 to Alzheimer’s 156 disease and heart disease157.  
Protein networks & cancer 
It has been proposed that an analysis of the key properties of proteins implicated in 
cancer in protein networks will guide the discovery of candidate targets for 
therapeutic intervention158,159. Contrary to the location of inherited disease genes in 
protein networks, the somatically mutated genes in cancer have a tendency to be 
found as central hubs in protein networks130,151. This notion of cancer genes having 
central roles in protein networks was also put forward by evidence of differentially 
expressed genes up-regulated in lung squamous cell carcinomas having significantly 
higher number of interactions partners in the human protein network 160. Similarly, an 
investigation of the known tumor suppressors and oncogene proteins 161 indicated that 
they have double the number of interaction partners when compared to non-cancer 
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proteins 162. However, this evidence may be result of the bias in cancer proteins being 
studied far more often, and therefore over-represented in protein networks. For 
example, an analysis of 29 cancer differential gene expression studies against 22 
different metrics of network properties indicated no strong evidence for a large 
number of highly connected proteins, but a higher degree of interconnected modules 
or groups clustering among cancer proteins163 was found. It is clear that somatic 
mutations are frequently involved in functional canonical pathways, as was revealed 
by the DNA sequencing of 623 genes with known or potential relationships to 
cancer164. Furthermore, a network strategy based on the analysis of mutations within 
network modules in several cancers identified rare cancer driver mutations involved 
in key cancer pathways. In that study, the genes identified do not play a central role in 
the pathways, but rather contribute greatly to a more refined tuning of function of 
these modules through possible crosstalk mechanisms165. It is clear that a focus on a 
modular analysis of groups of interacting proteins that correspond to protein 
complexes or functional networks, rather than a linear pathway analyses, are proving 
enormously effective in prioritizing the molecular factors of cancer progression166,167. 
A modular analysis of cancer protein networks has proven to unravel complex 
intertwined oncogene RAS pathways in cancer cell lines, whose functions are 
connected to processes that mediate sensitivity to drug response168.  The observation 
of the phenomenon of crosstalk in cancer protein network modules was important in 
that particular study, and strategies are being developed to capture proteins and 
protein network modules that cross talk with each other169.  The phenomenon of 
protein network modules cooperating with each other to confer the phenotype in a cell 
has been modeled using Boolean logic to indentify protein network signatures that 
have significance to clinical and biological outcome 170.  These and many other related 
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studies highlight the utility of dissecting protein networks to help us understand the 
cells complex phenotype.  
  5
Complex networks of tumor immunity 
Molecular complexity of the immune system 
Similarly to tumor cells, there is a substantial amount of signal transduction, with 
frequent and diverse crosstalk and sharing of protein components, among signaling 
protein networks in immune cells49,171. For the immune system, this is primarily 
cytokine-mediated cellular communication171,172. For example, the IFN-γ protein 
network is implicated in crosstalk to multiple signaling cascades, other than its well-
characterized regulation of activation of the STAT1 gene expression program. For 
now, the crosstalk behavior of IFN-γ is not comprehensively understood173. This 
makes IFN-γ protein networks an exemplary target for discovery of immune signaling 
in complex protein networks. The transduction of information signals through these 
very complex protein networks makes it a daunting task to elucidate biological 
meaning, not least for immunologists who treat signal transduction in networks as 
linear canonical pathways174. The traditional approach to understand the immune 
system by immunologists has involved deconvoluting the complex heterogeneity of 
immune cells with flow cytometry, using combinations of markers to define 
signatures that represent specific lineages, differentiation states, and functions. This 
strategy of studying complex immune phenotypes on a single protein basis is easily 
measured, visualized and interpreted. However, to capture a true understanding of 
immune phenotypes involves identifying dynamic changes distributed across complex 
networks of proteins. This is far more challenging. Furthermore, the current biological 
models of complex human immune system signaling are based on an over-reliance on 
the mouse model, which has been disappointing in the study of human immunological 
diseases 175. The mouse has 65 million years of evolutionary distance from human and 
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in research environments is subject to a skewed immunological profile due to an over-
abundance of homozygous recessive mutations, caused by excessive inbreeding 176. 
Global approaches to immunological discovery  
New strategies are currently evolving to address these challenges, and now a global 
view of human immune signaling is emerging177. These strategies are computational 
in nature and are progressing from initial efforts in computational immunology to 
building of immune databases 178,179 to computational network modeling approaches180-
182
. A global approach to capture modules or communities of proteins has been 
applied, and has successfully identified canonical pathways implicated in the mRNA 
expression changes in patient blood during the immune response to lupus 183.  Another 
systems approach developed a vaccine-behavior prediction method that performed 
with very high accuracy184. These and other studies signify an emerging trend of 
applying computational methodologies designed to support a systems-scale analysis 
of the immune system177.  
The future progression of these approaches is very much dependent on accurately and 
comprehensively mining and capturing protein network modules that are significant 
for the immune response. Prior to the extraction of protein network signals from 
patient samples, there is the seemingly difficult challenge of clarifying the definition 
of an immune gene. There are several international efforts underway to make these 
definitions and catalogue immune genes into databases 185-187.  The methodological 
development that comprises the strategy outlined in Paper II of this thesis, describes 
a great deal of disparity and disagreement in these immune gene databases188. In 
addition, that study implicated a great number of genes associated to the immune 
response, as yet uncharted by contemporary immune gene databases.  
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Protein network approaches & the immune response 
There is strong evidence linking genes of immunological diseases to highly 
interconnected modules or clusters in protein networks. This was shown to be the case 
recently when analyzing 150 different GWAS loci tightly associated to immune 
diseases and demonstrating an abundance of highly connected protein interactions 
between the protein products of genes in these loci189. Faced with the complexity of 
immune cell signaling49 and the plethora of possible cytokine interactions in tissue190, 
network approaches to dissect the functional association from protein networks in 
immune phenotypes is warranted. Many such research projects have already begun in 
this direction. For example, a microarray-based study in blood leukocytes, stimulated 
by bacterial toxins, applied a network analytical approach to identify novel protein 
network modules that correspond to the molecular machinery that responds to 
inflammation and a septic shock, during the innate immune response191. Another 
recent study used a systematic experimental approach to treat macrophage cells as a 
conceptual “black box” for deduction of the properties of the protein-signaling 
network upon stimulation of cell receptors by six different “input” cytokines 192. Their 
results suggest that the complex nonlinear networks in normal immune cells have a 
limited number of “outputs” (secreted cytokines), from the multitude of possible 
outputs. Therefore, complex protein networks are tightly regulated and controlled in 
the normal cell. Understanding aspects of this regulation would require completed 
large-scale protein network screens of immune cells. This has been achieved recently 
in B-cells using co-immunoprecipitation experiments and subsequent assembly of B-
cell specific protein networks. Coupled with algorithms to interrogate this network, a 
valuable resources was created to allow for an elucidation of the phenotypes that 
control the complexity of B-cell regulation 193. In that particular study, two novel 
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master regulators of the humoral immune response were discovered193. Furthermore, a 
recent effort that is seminal to protein network analysis at large, and specifically to 
tumor immunity, is the global protein network screening followed by a functional 
network analysis identified for IFN-γ signaling194. A pathogenic role of T-helper 1 
(Th1) cells and IFN-γ in autoimmune diseases and cancer raises the question of 
mechanisms by which IFN-γ contributes to pathogenesis, which could be answered by 
network analysis of this resource194 . The interactions between such inflammatory 
cytokines are currently being scrutinized for their involvement in modulating growth 
of invasive tumor cells195, and cancer stem cells in the tumor microenvironment196. 
Attempts of transforming these developments of protein interaction network analysis 
are now ongoing in the clinical arena, where gene expression analysis of circulating 
immune cells linked to their protein interaction has been shown to identify pathogenic 
network signatures197.  
Tumor immunosurveillance: a brief historical perspective 
During the 1700s, it was recorded that certain infectious diseases could have a 
beneficial therapeutic effect on malignant tumors198. This beneficial effect and 
regression of tumors was observed in certain cancer patients that developed bacterial 
infections198. The German pathologist and father of cellular pathology, Rudolf 
Virchow, documented influential observations in 1863 of the “lymphoreticular 
infiltrate”, linking the origin of cancer to sites of chronic inflammation 199. Later, the 
American physician William B. Coley in the 1890’s began to pursue the relationship 
of immunity and cancer, when he noted that some sarcoma patients who had severe 
post-operation infections at the tumor site, underwent spontaneous and sustained 
tumor regression200. He, among others during that period, followed up with very 
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controversial experiments, with beneficial clinical outcomes, involving the deliberate 
induction of erysipelas (Streptococcus pyogenes) in cancer patients, with the intention 
of bringing their malignancies under control200,201. The concept that the immune 
system could eliminate primary tumors naturally, in the absence of external 
therapeutic intervention was first proposed in 1909 by Ehrlich202. This has been a 
point of heated debate and was not resolved until the acquisition of solid molecular 
evidence in recent years203.  
Thomas and Burnet coined the term “immunosurveillance” for this hypothesis, and 
developed the concept further during the 1960s 204-206. Jonas Salk wrote a very 
forward-thinking essay on this topic in 1969, where he proposed that chronic 
infections, allograft rejections, autoimmune disorders and cancers belong to a 
common phenomenon known as “delayed allergic reaction”207. This line of research 
began to develop in an era when experimental models were finally becoming 
available to test the immunoesurveillance hypotheses. However, using mutated mice 
models that rendered an inactive immune system in the animals (nude mice), results 
were derived that contradicted the hypothesis. There was clear evidence indicating 
that the nude mice did not develop spontaneous tumors208 209. When no difference in 
primary tumor development was found between these mice and wild-type mice, the 
immunosurveillance concept was largely abandoned. 
The broad acceptance of the phenomenon did not take hold until as late as the 1980’s, 
when it became apparent that nude mice models were immune-compromised, but not 
completely immune-deficient. The nude mice model used in previous studies did not 
completely lack functional T cells210. In the years that followed, the proteins 
responsible for immune mediated tumor suppression began to be identified. The pro-
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inflammatory cytokine IL-2 was shown to clearly contribute to tumor regression in 
metastatic melanomas211, and IFN-γ prevented tumor formation in mice212,213. 
However, IFN-γ was also shown to collaborate in selecting for tumor cells with 
reduced immunogenicity, leading to malignant cells that are more capable of 
surviving against immune attack214. This explained possibly why immune competent 
individuals still develop cancer. These paradoxical roles of the immune system on the 
development of a tumor, prompted a re-definition of the cancer immunosurveillance 
hypothesis in recent years into cancer “immunoediting”203,215,216.  This now accepted 
phenomenon has taught us that the immune system plays a dual role in response to a 
tumor. It can suppress tumor growth by killing cancer cells or by inhibiting 
outgrowth. It also can promote tumor progression by selecting for invasive tumor 
cells or by establishing favorable conditions within the tumor microenvironment. That 
which is not understood entirely, are the complex protein networks that mediate this 
process within and between cells in the tumor microenvironment. 
Global approaches to tumor immunity  
With the advent of high-throughput technologies and more robust experimental 
models in immunology, there has been a rapid increase in the number of identified 
molecular players implicated in the tumor immune response172,217-219. This increase in 
evidence for relevant immune factors comes with increased complexity in the 
networks of relationships between these molecular players. This corresponds with the 
now accepted paradoxical biological and clinical outcomes that the immune system 
has on a tumor220. In turn, these revelations are coupled with the increasing trend of 
large-scale studies to capture the complete maps of protein interactions that regulate 
the major players, such as that of the recent screening of IFN-γ protein network194. 
  ,
This will offer us a resource to an increasingly detailed perspective of IFN-γ and its 
mechanisms of complex crosstalk in protein networks173. With the continuous increase 
in such large-scale screens, we are soon on the road to the discovery of a complete list 
of molecular players, and a map of the complex networks that contribute to the 
relationship between immunity and cancer. With this comes the necessity to develop 
computational strategies to mine, organize and decipher the complex protein networks 
that govern the balance between immune tolerance, promotion or rejection of a 
malignant tumor. 
Protein networks & immunity in the tumor microenvironment  
So, it is now well established that cancer is an inflammatory disease217-219,221,222 and 
that immune cells are recruited to and infiltrate into the microenvironment of a 
tumor223,224. There is increasing amount of recent evidence suggesting that some 
patients with cancer can mount an antitumor immune response that has the potential 
to control or eliminate cancer223. Numerous reports have appeared in the literature 
confirming that the infiltration of immune cells into a tumor plays a crucial role on the 
survival of patients. In these patients, an immune response signature (i.e. a 
community of genes) has been described, that is associated with improved outcomes 
in several tumor types. This has been reported for colorectal cancers 225, follicular 
lymhpomas226, melanomas227 , and ovarian cancers 228. T-cell environments that 
secrete cytokines such as IFN-γ generate acute inflammation that results in expansion 
of natural killer (NK), cytotoxic T cells (CTLs), M1-macrophages, tumor destruction, 
and the potential control or even elimination of cancer214,216. These signatures are 
associated with Th1 immunity and acute inflammation, similar to graft rejection. In 
more aggressive malignancies, immunosuppressive environments are described that 
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promote tumor proliferation, and protect the tumor from immune attack or clinical 
interventions229,230. This is inflammation of a different type, a chronic inflammation 
characterized by the IL-6 cytokine217,231. A term often used to describe this phenotype 
is “smoldering inflammation”217, and is an environment that is similar to wound 
healing mediated by Th2 cells232. It produces the cytokines IL-4 and IL-13, TGF-β, 
which suppresses anti-tumor Th1 immune responses, and EGFR ligands, which 
promote tumor growth and metastasis232,233. 
Regardless of the direction of the immune response toward a tumor, the phenotype 
outcome in the microenvironment is mediated by complex protein networks that 
promote inflammation in cancer development229,234. The type of protein interactions 
presented to immune cells will then affect the type and nature of protein interactions, 
and thereby the immune response by those cells. These protein networks are both 
intrinsic in, and extrinsic to, all cells in the tumor microenvironment: normal, 
fibroblasts, sentinel-immune, endothelial, tumor, infiltrated immune cells, etc. During 
cancer progression, dynamic protein interactions occur between tumor cells and host 
immune cells that may function to either stimulate or inhibit cancer growth. These 
protein interactions also facilitate various cells to communicate with other cells in the 
local microenvironment, by secreting various protein-interacting cytokines and 
growth factors, or hosting these factors on their cellular membranes. These complex 
immune phenotypes are a challenge to capture from the tumor microenvironment. 
Methodologies to quantify the immune phenotype in tumors were developed in Paper 
II of this thesis, to address these challenges188.  
The entire complement of these factors is called the “secretome”. This term was 
coined by a review in 2009 that summarized evidence suggesting that the secretory 
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phenotype of senescent cells fuels inflammatory responses that in turn recruit immune 
cells to create immune clearance phenotypes235. Secreted cytokines and chemokines 
are manifested by all cells and is a process that becomes increasingly complex during 
cancer progression. This is especially so in the immune clearance of oncogene 
induced senescent cell in cancer236. The delicate balance in the tumor 
microenvironment, switching between immune-surveillance, -tolerance, or –escape, is 
dependant of the nature of activation of the adaptive immune system.  
Th cells & protein networks: inflammatory switches  
Disrupted T helper cell (Th) responses can cause a range of diseases, including 
cancer. The Th-cell responses are coordinated through distinct functional protein 
networks, governed by distinct programs of transcription factors that ultimately have 
distinct consequences for a malignant tumor. They recruit to the microenvironment, 
and activate other immune cells to respond to a progressing tumor. These activated 
and recruited cells include B cells, NK cells, macrophages, mast cells, neutrophils, 
eosinophils and basophils. Th-cells regulate these immune responses via the 
production of specific cytokines, which act as messengers to instruct other cells of the 
immune system. There are currently four defined CD4 + Th-cell subsets: Th1, Th2, 
Th17 and Treg cells237,238. Th1 is characterized by the stable expression of the cytokine 
IFN-γ, and coordinates tumor-killing responses. Conversely, Th2 is characterized by 
the stable expression of IL-4 and coordinates metastatic tumor-promoting responses. 
The classic paradigm from its conception in 1986239, was that the Th lineage was 
thought to exist strictly in a dichotomy between the Th1 and Th2237,240 cell lineages, 
i.e. Th1 and Th2 were stable states expressing a clearly defined output of cytokines, 
and were antagonistic regulators to each other. For some time, Th1 and Th2 were 
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considered to be the only types of CD4+ effector responses.  However, the latest 
experimental reports contradict this dichotomy. In fact, it has become apparent that 
CD4 + T cells undergo a complex process of differentiation enacted through complex 
signaling networks. Th cells differentiate not only into stable lineages of Th1 and 
Th2, but also into two other major lineages: Th17 and Treg cells237.  
This process is dependent on the functional interaction stimuli received by the naïve 
CD4 +T cell, the pattern of cytokine secretion of the various lineages and the protein 
signaling cascade that leads to a defined expression of specific transcription factors. 
Th cells from different lineages secrete their characteristic cytokines, resulting in a 
much greater degree of heterogeneity of the Th cell population than was originally 
thought possible. In addition, the pattern of cytokine secretion switches from one 
lineage to another under different phenotype cues from the tumor microenvironment. 
This indicates that Th cells exhibit great plasticity in their lineage commitment, which 
has important implications for the fate of a developing tumor238,241,242. This plastic 
process of cellular differentiation of Th cells is akin to “decision-making” by the 
naïve CD4 +T cell precursor cell243-245.  This process is governed by complex, yet 
orchestrated, protein networks, which have clearly defined cytokine-inputs and 
cytokine-outputs. Thus, this can be seen as an ideal protein network cascade that can 
be analyzed using computational networks modes as is done in Paper I of this 
thesis246, and other network studies of Th cell regulation247,248  
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Cellular machinery in protein networks  
Protein networks & networks of molecular machines 
Proteins rarely function alone 249-251. Therefore a sensible interpretation of complex 
protein networks in the cell will require an analysis of their actual mode of function. 
In physiologically relevant states, the peptide sequences of proteins are transformed 
into three-dimensional structures, which bind stoichiometrically to other peptide units 
at the same time and cellular location, to form a quaternary structure, i.e. the 
“molecular machine” or protein complex252. These are the actual functional structures 
that carry out most processes in the cell, such as the ribosome or membrane synapse 
of a T cell. It is becoming increasingly apparent that new approaches are needed to 
transform the rich information in protein networks into knowledge of these molecular 
machines251. In order to achieve a complete understanding of cellular complexity, the 
detailed mapping and structural analysis of molecular machines in the cell needs to be 
carried out251. This will entail massive efforts in the identification, isolation, structural 
characterization and mechanistic analysis of these machines252,253. Computational 
prediction methods may be valuable in this endeavor254,255.  Traditionally, many 
protein network studies have treated the fundamental unit of function in cells as the 
proteins. In Paper III, using the most comprehensive databases available on 
yeast256,257 and human258 protein complexes, the complexes are treated as nodes in 
cellular networks, and “higher-order” interactions are predicted between these units.  
Permanent & transient protein interactions  
The binding affinities of the protein interactions are important features of protein 
complexes. Protein interaction can be categorized into two types based on their 
binding affinities to each other. Permanent protein interactions usually form stable 
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structures together in molecular machines. Transient interactions are less stable. They 
associate and disassociate from each other quickly and temporarily259,260. In the current 
status of knowledge in protein network databases, interactions are not annotated into 
the two categories. In the cell, there is a continuum existing between transient short-
lived interactions and permanent interactions found in stable functional molecular 
machines, making it difficult to resolve which interactions are corresponding to 
protein complex formation, from the short-lived transient interactions260. These 
dynamics very much depend on the physiological conditions of the cell261. The protein 
networks in existence today underlie both of these inter-mixed categories of protein 
interactions. Many proteins are involved in more than one protein complex and binary 
interaction. These complex features need to be characterized in terms of their detailed 
structures and kinetic mechanisms in order resolve completely the complexity of 
protein networks.  
Methods to identify transient interactions between proteins are being improved and 
facilitated constantly by the accumulation of protein network data from proteomics 
and structural biology262. Continuous development of technologies that are fine-tuned 
for the detection of weak protein interactions and their structural features263 will 
complement many computational approaches to understand their role in complex 
protein networks. The incorporation of the detailed biochemical and structural 
information of molecular machines can convert an entangled complex network of 
binary protein interactions into accurate biological models.  The growth of these 
protein complex structures and their dynamic properties will improve on 
computational procedures to predict novel relationships in complex protein 
networks252,254, such as that reported in Paper III, i. e. to predict the higher order 
complex-complex interactions.  
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Protein complex databases and proteome-wide maps 
There are increasing large-scale efforts to build an accurate perspective of the protein 
complex repertoire of cells. Such proteome-wide interactome maps are emerging over 
the past ten years, offering increasingly comprehensive data on binary protein 
interactions and protein complexes. These exist for many organisms, including E. 
coli264, yeast65,265 and human63,64. The next generation of these proteome-wide maps are 
adapting to acquire, more comprehensively, experimental data to provide evidence for 
the interactions between stable complexes266,267. In these next generation proteomic 
studies, large-scale laborious efforts using a wide range of proteomics toolkits across 
several laboratories have attempted to capture experimentally the global organization 
or “complexome” of human 267 and Arabidopsis266 protein complexes.  
These developments are complementary to the goal of computationally inferring this 
knowledge, from manually curated complexes and binary protein interaction maps, 
such as that attempted in Paper III. These inter-complex interactions are difficult to 
experimentally detect precisely, without erroneous inferences and assumptions. They 
therefore necessitate some degree of statistical inference to rank relevant inter-
complex protein interactions. With the advent of a growing number of these 
experimental resources of protein complexes, comes an increase in specialized 
databases to store and organize this information. Outside of the protein network 
databases mentioned previously, there are dedicated databases of manually curated 
protein complexes for various organisms that are proving to be very useful for 
proteomic studies71,256-258,268 
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Aims of the study 

This study had two main objectives: (1) To develop computational strategies to 
provide a broadened understanding of complex protein networks in the cell, with 
particular application to immune cells critical to cancer progression. (2) To treat 
protein complexes as the functional units in the complex protein networks of the cell 
and predict networks of interactions between these units. Thereby, attempting to 
resolve the complexity of the cell by treating it as a functional network of interacting 
molecular machines.  
The study attempted to achieve these goals through developing and applying logical 
protein network models in a cellular phenotype within a clearly defined immune cell, 
i.e. Th cell differentiation. In addition, strategies were devised to quantify the 
immunological phenotype in cells of complex tissues, specifically tumors, and to 
allow the identification of immune related protein networks linked to cancer 
progression. The purpose of these undertakings was to achieve an improved 
understanding of cellular organization and protein network complexity, making an 
abstraction in cellular protein networks to their core biochemical components, i.e. 
molecular machines and predict interactions between these protein machines.  
The following are the specific aims related to each of the three papers:  
I. To apply a Boolean model regulatory network, based on an extended signal 
transduction network and directed protein interactions implicated in Th cell 
differentiation.  The intent was to improve our understanding of the complex 
networks implicated in the differentiation of T helper (Th) cells into its 
regulatory lineages. Further to this the goal was to examine whether this 
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network approach could assess the Th1/Th2 paradigm with respect to its 
compatibility with a counter regulatory role of the Th1/Th2 lineages.  
II. To develop an integrative computational approach that quantifies the 
immunological relevance of all genes in the human genome. The specific goal 
of which was to capture and quantify the signatures implicated in the immune 
response during cancer progression, from large-scale measurement of genes 
detected in high-throughput experiments.  Further to this, the goal was to map 
this quantitative immune information to protein networks, to provide insights 
to further hypotheses on the mechanism of the tumor immune response during 
cancer progression  
III. To investigate globally the biochemical mechanisms in protein networks by 
abstracting protein networks the level of molecular machines (protein 
complexes). Interactions between these molecular machines were predicted, as 
well as the use of these interactions as representative model of cellular 
networks  
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Summary of the Papers 

Paper I 
In this paper, a network analysis of Th cell subsets, namely Th1 and Th2 cells, was 
carried out. This allowed an assessment of the long held conception that these Th 
subsets counter-regulate each other to orchestrate inflammatory responses. 
Understanding these dynamics would allow for future studies on how alterations in 
their balance may result in different inflammatory and autoimmune diseases. This is 
particularly relevant in cancer, where the Th status of the tumor microenvironment is 
critical to clinical outcome. This paradigm of the Th1/Th2 balance has been 
challenged by recent clinical and experimental evidence. There are a large number of 
genes involved in the signaling cascades and regulation of Th cell differentiation, and 
therefore an assessment of the Th1/Th2 paradigm by modeling or experimentation has 
been very challenging.  However, a recently developed novel algorithm caters for the 
analysis of much larger model Boolean logic networks269. Using this, combined with 
other levels of computational analysis, such as in silico knockouts, and gene 
expression microarray data from human T cells, we examined if a network model was 
compatible with a counter-regulatory role of Th1 and Th2 cells.   
We constructed a directed network (including aspects of activation and inhibition) of 
genes regulating Th1 and Th2 cells through a combination of literature mining and 
manual curation. Application of the Boolean model on this network identified four 
attractors in the network, three of which included genes that corresponded to Th0, 
Th1 and Th2 cells. The fourth attractor contained a mixture of Th1 and Th2 genes. It 
was found that neither the in silico knockouts of the Th cell attractor genes nor the 
gene expression microarray data from patients with immunological disorders and 
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healthy subjects supported a counter-regulatory role of Th1 and Th2 cells. These 
attractors were identified along with an additional attractor we named ThX. In some 
respects this may reflect the current biological understanding of rapidly changing 
Th1/Th2 paradigm. Overall, this paper indicated that combined network modeling, in 
silico knockouts and gene expression microarray analyses, is a tractable approach to 
unravel the complex signaling and regulatory networks of cells. 
Paper II 
It is clear from some of the outcomes in Paper I, that there is great deal of unresolved 
complexity, most of which is not yet understood or acquired, associated to Th cell 
populations. Recent evidence suggests that the immune component of the tissue to 
which the Th and other effector cells of the immune system migrates to determines 
their final differentiation state270 Therefore, identifying the immune molecular 
components and quantifying their signal in complex tissue, not least in tumors, would 
be very beneficial for future studies in understanding this complexity. This was the 
motivation behind Paper II of this thesis. 
The immune signal in complex tissue, not least in tumors, is complex and difficult to 
characterize. For example, immune gene expression as detected in high-throughput 
experiments originates from the combination of tumor, fibroblasts, endothelial, and 
immune cells in the microenvironment. Developing strategies to capture and quantify 
this immune component would facilitate the characterization of the poorly understood 
roles immunity plays in cancer progression. Currently, the approaches applied to 
profile the immune component of tumor fall short in achieving this goal.  Analysis of 
the immune component of a tumor currently relies on incomplete identification of 
immune factors and their associated protein networks, primarily using manual 
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approaches. In Paper II, an immunological relevance score for all human genes, was 
developed using a novel strategy that combines literature mining and information 
theory. Using this score, an immunological grade can be assigned to gene expression 
profiles in a sample, and thereby quantify the immunological component of tumors.  
Measures were taken to benchmark this score against existing manually curated 
immune resources, as well as against results from high-throughput studies. To further 
utilize immunological relevance for genes, the relevance score was charted against 
both protein networks and cancer information. This forms an expanded interactome 
landscape of tumor immunity. We applied this approach to expression profiles in 
melanomas, thus identifying and grading their immunological components, followed 
by identification of their associated protein networks. 
The assignment of a ranked immunological relevance score to all human genes 
extends the content of existing immune gene resources and enriches our 
understanding of immune involvement in complex biological networks. The 
application of this approach to tumor immunity represents an automated systems 
strategy that quantifies the immunological component in complex disease. 
Paper III  
At the very core of complex protein networks in the cell are the biochemical 
mechanisms of function. These are enacted through protein complexes, or molecular 
machines. These units of functions are at the fundamental basis of all processes in the 
cell. To truly unravel the complexity of process such as Th cell differentiation, as 
approached in Paper I, it may be necessary to abstract the unit of function in the 
networks to that of the groups of protein that assemble as one entity to enact that 
function. This information however is incomplete, and although efforts such as those 
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in Paper II may help in acquiring more complete an accurate knowledge of the 
mechanisms, there is an abundance of ground yet to be achieved in understanding 
how these structure operate at the cellular level. It would therefore be highly 
informative to analyze cellular proteomes as networks of these interacting molecular 
machines. This was the first human study to treat true manually curated protein 
complexes, not their individual protein members, as the functional unit in cellular 
protein networks, and to predict interactions between them. To that end, we utilized 
expertly curated protein complexes and experimentally validated protein networks, 
and designed a statistical null model that randomized the membership of the protein 
complexes, but preserved their degrees in the protein networks. This statistical 
approach successfully identified the pairs of complexes in both human and yeast, 
where the number of corresponding protein interactions between them is due to an 
actual physical interaction between the complexes. An evaluation against a set of 
expertly curated yeast complex-complex interactions revealed that approximately 
50% of these relationships could be predicted in this manner. A network analysis of 
high scoring complex-complex networks revealed a biologically sensible organization 
of the cell into functional networks of complex-complex interactions. Such high order 
analyses of cellular proteomes can lead to improved understanding of little understood 
cellular processes, and guide the discovery of novel relationships between molecular 
machines. 
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Discussion  
Methodological & Biological perspectives 
Validity of the Boolean networks   
The Boolean network approach applied in Paper I246 was more comprehensive than 
those attempted previously on T-cell differentiation 248. The Th1 and Th2 cells have a 
phenotype defined by the release of individual signature cytokines, i.e. IFN-γ and IL-
4, respectively. Previously it was thought that these cell types exist in a dichotomy 
whereby they co-regulate each other to coordinate the immune response239,240. 
However, recent evidence suggests that these two Th cell subtypes do not behave in a 
dichotomy of counter regulation. A novel algorithm was applied that allows the 
Boolean analysis of large networks269 to model this phenotype outcome. It could be 
argued this new algorithm was not taken full advantage of in our approach. Several 
formal methods can be used in order to analyze steady states of a Boolean network to 
find all attractors. We tested both Binary Decision Diagrams (BDD)271 and the 
approach of Boolean Satisfiability (SAT)269 which allows the modeling of much larger 
networks. Although we expand the existing model248 of Th cell differentiation from 14 
to 51 genes, alternative methods, such as BDD, may have worked just as well on a 
network of this size. However, BDD and other decision diagram-based algorithms 
have limited capacity due to the excessive memory requirements for large networks. 
The reason for the limitation to 51 genes from the total 403 genes identified from 
literature mining the 20 million articles in Medline, was based on careful manual 
curation. Only well-defined interactions for Th1/Th2 cell differentiation were 
included. The relevance of this curation is substantiated to a certain extent by the 
analyses of gene expression data from patients with immunological disease. However, 
the limitation of a manual curation process in assigning the Boolean model 
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construction, by building the positive (activation) versus negative (inhibition) 
interactions statements, may have reflected the bias of the current knowledge in the 
field toward the Th1/Th2 dichotomy. Therefore, there is scope for expansion of this 
study to a more complete Boolean model constructed from all known genes 
associated to Th cell differentiation, extracted from the literature, where the 
directionality of the positive and negative statements are incorporated. The 
painstaking task assigning these rules manually may be avoided during the 
development of more intelligent literature mining algorithms that can capture 
activation/inhibition relationship automatically and accurately from unstructured text. 
Efforts in Paper II to identify and quantify immune phenotypes from complex tissue 
could also be applied in order to expand the limitations of existing Boolean models to 
unravel the complexity of this process in Th cells.  
Synchronous vs asynchronous Boolean updating  
The method applied to the Th network was designed to identify the steady states of 
Boolean networks under synchronous updating. This is an update scheme that 
assumes equal timescales for all interactions in the network. Such an assumption 
seems unlikely in a real living cell, as there are inter- and intracellular interactions as 
well as enzyme reactions and transcription, dynamically occurring at different time 
points. It has been well-established271,272 that under asynchronous updating, the same 
initial state may lead to different steady states or attractors. This asynchronous 
updating could lead to different and more biologically accurate results. However, the 
data on Th cell differentiation that is available is only qualitative. Due to this 
limitation, and the example set by previous attempts248, synchronous updating was 
chosen. However, the modeling of Th cell differentiation using asynchronous 
updating is very important for future research directions. This could be performed 
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based on biological input data, such as time-series gene expression microarray studies 
of Th cells polarized into the various lineages. 
Plasticity of the Th cell lineage  
This fourth attractor identified in the Boolean network model in Paper I did not agree 
with a counter-regulatory role of Th cell differentiation. This finding, however, does 
comply with the most recent empirical evidence on the “plasticity” and heterogeneity 
of Th cell types and differentiation
238,241,273
. An increasing number of Th cell subsets 
have been discovered, for example Th3274, Th9275, Th17276,277 and Th22 278. An 
important conceptual problem that comes with network modeling of this newly 
discovered range of Th cells based on one cytokine output is that each subset 
expresses up to thousands of different proteins. There is a very large portion of these 
proteins, which overlap any two Th subsets. Each Th subset may have substantial 
phenotype similarities apart from that exerted by its signature cytokine. Thus, sub-
classification based on one cytokine/subset may only reflect a fraction of the 
functionality of each subset.  
Th cells are not only heterogeneous, but also plastic in their lineage fates. Their 
signature cytokines are released in complex protein network patterns242, so that one 
lineage may change to another and back to the original lineage 242. This process, and 
the protein interaction networks that mediate it, is not completely understood, 
especially in vivo. The sub-classifications of Th cells are largely based on in vitro 
studies, under conditions that may or may not resemble those in vivo. For example, in 
vitro Th cell polarization is induced by a fraction of the proteins involved in vivo. 
Another problem is that in vivo cells other than Th cells may release Th polarizing 
proteins (epithelial cells, mast cells and eosinophils). Ideally, a protein network model 
should comprise representative interaction networks from all these cells. This is a 
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formidable challenge, given the complexity of each network and the limitations of 
currently available information. Improved methodologies for extraction of these 
protein networks from the literature and analysis of single cells in vivo are likely to 
contribute to addressing this challenge. 
Master regulators of Th cell plasticity  
As discussed above, the Th cell is complicated by Th plasticity and great 
heterogeneity. Traditionally, Th cell classification has been discrete, rather than 
continuous, and mainly based on individual cytokines or transcription factors. 
However, Th plasticity implies continuous and transitional states through the other Th 
lineages. These transitional states are currently poorly characterized. However, in the 
context of Th1 and Th2 cells studied in Paper I, GATA3 has been shown to induce a 
transition from Th1 to Th2 cells 279. Since Th1 cells are associated with TBET and 
Th2 cells with GATA3, this implies that TBET and GATA3 may oscillate between 
Th1, Th2 and transitional forms. This is supported by the description of TBET at low 
levels in Th2 cells and GATA3 in Th1 cells 280,281. Similarly, IRF4 and STAT1 are 
expressed in both Th1 and Th2 cells282. Thus, the group of cells referred to as ThX 
may represent a transitional state between Th1 and Th2 cells. However, there is major 
limitation to capture this plasticity in it entirety in Paper I. For one example, the 
exclusion of FOXP3 in the manual curation step is a limitation. This transcription 
factor is a key component for Treg cell differentiation283. Therefore, it could be argued 
for the presence of a too strong a bias in the network modeling approach on the Th1 
and Th2 cell differentiation to capture the plasticity of the Th cell lineage. For a 
comprehensive understanding of how Th cells orchestrate immune responses in the 
tumor microenvironment, it would be appropriate to capture also the dynamics of 
Th17 and Tregs, given the evidence of their role in mediating breast cancer metastasis 
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to the brain230 
The epigenetic mechanisms of Th cell fate 
That which is not considered directly in the Boolean model of the Th regulatory 
network in Paper I, is the epigenetic mechanisms that govern the Th cell fate284-286. 
The fate and maintenance of a Th cell precursor is very much dependent on the 
genome organization of the cell at any given phenotype state287.  Dynamic chromatin 
remodeling can result in increased accessibility of the cytokine genes responsible for 
differentiation to transcription factors. Furthermore, chromatin remodeling can induce 
the silencing of cytokine expression of the alternative phenotypes by restricting access 
to transcription factors, and through methylation of DNA284,286.  Evidence of 
epigenetic factors in Th differentiation emerged as early as 2001, when assessment of 
Th cells removed from one set of polarizing conditions and placed in conditions to 
induce the alternative cytokine program, demonstrated that this plasticity to change 
was lost after three or four cell divisions288. The protein network model analyzed in 
Paper I falls short of analyzing these features, but future networks studies would 
necessitate the incorporation of this information in order to unravel the complexities 
of this process. 
These epigenetic mechanisms, it could be argued, occur at the level of the molecular 
machine, i.e. the protein complex. Already inherent within the known network of 
protein interactions lies a great deal of complexity. Developing a formal 
representation of the complex network of interacting molecular agents in the cell is 
important to develop accurate simulations of the cell, and will lead to an improved 
understanding of its dynamics. This biochemical machinery of the cell is the most 
valid agent in network models. Also, when analyzing protein networks, it may be the 
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most informative. To accurately model these mechanisms, requires knowledge of how 
the protein complex machinery in nucleus compartments interact with each other, 
resulting in genome conformations that oscillate with signal transduction. We are 
some way away from achieving this in its entirety39. One step in progress towards this, 
however, is to have the ability simulate an accurate map of the protein complexes that 
in turn recruit and interact with other protein complexes to bring about this genome 
conformation. The approach developed in Paper III attempted to predict interactions 
between stable complexes and may possibly guide experimentation to identify these 
epigenetic relationships in the years to come.   
Tumor tissue heterogeneity & complex protein networks 
The current understanding of cancer biology places increased emphasis on 
understanding the Th differentiation networks studied in Paper I, and how they 
mediate tumor immune responses in the tumor microenvironment224,240,289. There is 
incomplete knowledge of the important molecular players, and how they interact in 
complex networks. However, increased consideration of microenvironment related 
question is driving immunotherapy forward290. For now, these mainly using agents 
that block immunosupression networks291. However, as knowledge of the pathway 
mechanisms in the tumor microenvironment increases, it should be possible to 
develop new cancer therapies that are safer and more efficacious with respect to the 
specific microenviroment of each cancer patients. Having a complete and accurate 
knowledge of the immune components in the microenvironment one can target 
specific patients having high levels of inflammatory molecules, cytokines, 
chemokines, tumor-infiltrating T cells (TILs), dendritic cells  (DC) and/or 
macrophages. Developing a complete molecular understanding, and developing 
clinical applications, of immune-based cancer therapeutics require information on the 
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molecular networks that that will elicit a tumor-specific acute inflammatory response 
that induces tumor rejection. The tumor may be programmed through its complex 
molecular networks to express or release molecular signatures to activate IFN-γ/Th1 
type tumor-killing immune responses,270,292.  There is a need for computational 
strategies, like that of Paper II, to capture relevant networks of proteins to guide an 
understanding of the relevant cancer protein pathways and development of new 
treatments. By doing so, we can broaden our knowledge of the complex processes 
governing tumor immune responses. 
Information theoretic scoring of immune signals 
The immune environment of complex tissue dictates the stimuli received by Th and 
other immune cells in the peripheral lymph nodes or in thymus and their 
differentiation lineages293. Capturing and quantifying the immune information in 
heterogeneous tissue is a challenge and was addressed in Paper II. Phenotype 
information for the molecular players in complex cellular networks is latent in the 20 
million-plus articles of the medical literature, and it is reasonable that this could be 
used as a resource to quantify the immune phenotypes in genes in complex tissue. 
Medline is a rich resource of semantic information. However, it is a noisy 
communication channel emitting convoluted phenotype information for thousands of 
genes and much of the gene information in Medline is convoluted among multiple 
overlapping phenotypes. The principles of information theory and Shannon’s entropy 
were applied to deal with this challenge294. Shannon’s entropy was seen as a sensible 
measure to score the phenotype information content for genes from the literature. It 
required a once-off manual effort to achieve the task of building a lexicon of expertly 
chosen terms relevant for immunity. This lexicon was then treated as an information 
coding system for immune relevant signals. Thus, the literature association between a 
  5
gene and an immune phenotype term was treated as the observance of a “symbol” 
communicating the immune signal for that gene.  
Biases in the information scoring of immune phenotypes 
Many biases potentially exist in adapting such an approach to quantify phenotypes. 
For example, the many association captured from the citation principle that was 
used113 are possibly contrary to the relationship of the gene to phenotype being 
assumed in the indexed articles. It is difficult to solve this entirely and precisely using 
automated approaches. However, measures could have been taken to apply other 
principles of literature association than co-citation alone.  Another bias that may 
affect the contextual information content of a gene is the citation popularity of the 
gene itself in all of Medline, i. e. its probability of co-citation amongst all structured 
vocabulary terms (association to all possible phenotypes) in the entire information 
space of Medline. This bias can be quantified to a certain extent and it was corrected 
using the Kullback-Leibler (KL) or “relative entropy”295.  This correction created a 
more accurate measure of information content that was used as an immunological 
score for each gene.  
Multiple phenotypes in the tumor microenvironment 
The immune information score is a global measure encompassing 1921 immune terms 
from structured vocabularies or ontologies. It was not a score attributed to a specific 
phenotype or direction of the immune response. It was demonstrated to accurately 
rank and identify global immune network signatures, and suggest new genes that 
could be populated into immune databases. It was successfully applied to classify 
melanoma patient groups227,296, whose immune score corresponds to key clinical 
features of cancer progression or survival; in addition to identify the immune related 
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protein networks in these tumor microenvironments. The global score has also been 
used to detect an elevated immune response, accompanied by associated protein 
networks, within a group of early-onset colorectal cancer patients compared to a late 
onset colorectal cancer group297. However, that which is not achieved by the approach 
developed in Paper II is a quantification of immune information with respect to 
specific immune responses, and/or the directionality of the immune response. The 
immune score does not in an “unsupervised” manner, or without manual 
interpretation, detect the directionality of the immune response toward the tumor. The 
approach can be developed further, in an improved version, to assess whether the 
immune network signatures that it captures in the high-throughput measurements of 
tumor tissue are correlating with Th1 type tumor-killing responses, or with Th2 type 
tumor-promoting responses. There is a range of machine learning methods298 that 
could have been applied to detect these network signatures. There is a strong 
possibility that there is a lack of adequately annotated high-throughput experiments to 
successfully carry out such an endeavor. However, at the very least, the immune 
information score could be segmented into more resolute and discrete classes of 
immune phenotypes (NK, MI/Macrophage activity, etc). These then can be quantified 
in a similar scoring scheme, and related to their protein networks signatures to 
elucidate possible mechanisms behind these immune responses in tumors.  
Community detection in complex-complex networks 
Having identified high-confidence complex-complex interactions in the cell, it creates 
an opportunity to explore how such higher order relationships in protein networks 
relate to “communities” of interacting molecular machines. There were many possible 
options available to explore the communities of predicted complex-complex 
interactions. Community detection of groups of nodes in real networks has become a 
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central quest in network studies in the recent decade. 299-303. These have proven to be 
effective, although most do not capture features of how network components behave 
toward each other in real networks or systems in nature. This is also true for 
molecular cellular networks. In contrast to these previous methods in community 
detection, which have entirely focused on the grouping of nodes, a community 
detection algorithm was used in this study that naturally incorporated overlaps 
between the interactions between the molecular machines. In this way, a sensible 
biological organization of the interactome into functional communities of cooperating 
protein complexes is revealed.  
It was apparent that these interactions organized the complexity of cellular protein 
networks into sensible biological clusters. It would have been additional supportive 
evidence to this effect, if we had measured how these communities of complex-
complex interactions were organized according to their cellular compartments. This 
was not done systematically using statistical measures of ontology enrichment, for 
example, mostly because the majority of the complexes in the source databases used 
were nuclear complexes, which would have biased such tests a priori.  
Additional observations from the protein complexome 
In the course of building the data framework to predict complex-complex interactions, 
a number of observations were made which were either relevant to the specific goal of 
Paper III, or interesting in themselves and possible topics for future studies. One of 
these was the great degree of similarity between complexes in humans. Similarity was 
quantified between two complexes in terms of the number of overlapping proteins. 
This was computed by the Jaccard index, and then complex pairs were clustered 
based on this similarity. There was a great degree of such clustering, with a large 
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amount of clusters in the human proteome. In yeast, however, clusters of similar 
complexes were small. Similarity in protein interaction partners in the protein 
network was also interesting. Proteins in the protein networks of the cell were 
considered “similar” if they had the same interaction partners (also quantified using 
the Jaccard index). The extent to which similar proteins exist and were found within 
the same protein complex was notable. It was generally found that proteins that had 
high degree of similarity in their interaction partners were enriched in the largest 
complexes. The possible genomic or evolutionary reasons for these phenomena were 
largely left unexplored in Paper III, and are open to questions for future studies. 
Concluding Remarks 
The statistical methodology applied to predicting complex-complex interactions, in 
some respects, addresses a real need to develop further bioinformatics and statistical 
tools that reliably capture the interconnected environment of the cell. It has become 
clear that the cell is replete with correlated patterns and complexities, and traditional 
tools fall short. Progress towards robust network approaches is limited by the 
incompleteness of the entire network maps of the cell, and knowledge of the 
biochemical mechanisms that underlie their function. 
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Future perspectives 
Designer circuits for personal cancer immunotherapy 
The future development in protein complex design and the emerging field of network 
biology, encompasses promising strategies to both understand the complex networks 
in the cell, and also to deliver targeted therapies to cancer patients.  This may have 
seemed unrealistic and overly ambitious only some few years ago, and as we are still 
many years to achieve this, it still may be considered an ambitious vision. However, it 
will be possible eventually to engineer functional molecular machines cooperating in 
complex cellular networks in living systems.  
The merging of the fields of nanotechnology, bioinformatics, systems biology and 
synthetic biology can bring about a revolution in targeted therapies in cancer. This 
can be explained by the following hypothetical scenarios:  (1) When we understand, 
finally, the complete dynamics of gene regulation in eukaryotic cells, using the 
toolkits developed in systems biology and brought to our comprehension in 
computational biology. (2) Using this acquired knowledge of gene circuitry in cells, 
we engineer synthetic circuits that will engage in a certain gene expression programs 
leading to the building of cellular machines that will carry out therapeutic actions 
through interactions with other cellular systems or cellular machines. (3) We use 
technologies developed in nanotechnology to effectively deliver these designer 
circuits to the target cells and tissues of a cancer patient. This will bring about true 
personal targeted molecular cancer medicine.  
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Realistic possibility to harness complexity  
Designer T cells encoding antigen bound molecular machines have recently achieved 
clinical effect. It has recently been reported how immunotherapy with these designer 
cells, derived from cells from the patient, can recognize and destroy malignant 
cells.304 Synthetic biology is developing rapidly towards harnessing gene circuits of 
increasing complexity305,306. The desire, ultimately, to construct and control molecular 
machines, fuels one of the great endeavors of contemporary biochemistry. This will 
be a major achievement in the future global approaches of computational 
biochemistry. Protein biochemists are making rapid advances in understanding the 3D 
structure of molecular machines combining nanotechnology engineering principles to 
construct them307,308. Finally, nanotechnology is making rapid advances in drug 
delivery and imitation of cellular systems.  As progress increases in understanding 
dynamic complex systems, mastery of structure, function and communication across 
the different protein machines will prove essential. 
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Combining Network Modeling and Gene Expression
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Abstract
Two T helper (Th) cell subsets, namely Th1 and Th2 cells, play an important role in inflammatory diseases. The two subsets
are thought to counter-regulate each other, and alterations in their balance result in different diseases. This paradigm has
been challenged by recent clinical and experimental data. Because of the large number of genes involved in regulating Th1
and Th2 cells, assessment of this paradigm by modeling or experiments is difficult. Novel algorithms based on formal
methods now permit the analysis of large gene regulatory networks. By combining these algorithms with in silico knockouts
and gene expression microarray data from human T cells, we examined if the results were compatible with a counter-
regulatory role of Th1 and Th2 cells. We constructed a directed network model of genes regulating Th1 and Th2 cells
through text mining and manual curation. We identified four attractors in the network, three of which included genes that
corresponded to Th0, Th1 and Th2 cells. The fourth attractor contained a mixture of Th1 and Th2 genes. We found that
neither in silico knockouts of the Th1 and Th2 attractor genes nor gene expression microarray data from patients with
immunological disorders and healthy subjects supported a counter-regulatory role of Th1 and Th2 cells. By combining
network modeling with transcriptomic data analysis and in silico knockouts, we have devised a practical way to help unravel
complex regulatory network topology and to increase our understanding of how network actions may differ in health and
disease.
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Introduction
The immune system is composed of diverse cell populations, for
example antigen-presenting cells, T and B lymphocytes as well as
effector cells like eosinophils, mast cells and neutrophils. One type
of T lymphocytes, called T helper (Th), has an important role in
regulating this cellular network. Th cells can be further divided
into Th1 and Th2 cells. Th1 and Th2 cells are thought to be
mutually inhibitory and also to be involved in different diseases;
Th1 cells are associated with autoimmune diseases, while Th2 cells
are involved in allergies [1].
Although considered a simplification, the Th1/Th2 dichotomy is
supported by a large body of experimental evidence [2]. However,
studies of human diseases are more ambiguous in terms of the
counter-regulatory roles of Th1 and Th2 cells. We and others have
found that allergy, which is mainly thought to be a Th2 disease, can
also be associated with Th1 responses [3,4]. One explanation could
be that the Th1/Th2 paradigm is, to a large extent, based on studies
of gene interactions in mice which may differ from those in humans,
[5]. Another important aspect is that Th1 and Th2 cells interact in
complex cellular networks that include several other T-cell subsets
and cell types [5]. Ultimately, the balance between Th1 and Th2
cells is complicated to study experimentally, because it is the net
result of altered interactions between multiple genes.
Gene expression microarray studies evidence that hundreds of
genes are involved in the Th1/Th2 cell differentiation [6]. We and
others have found that complex gene expression changes in diseases
can be addressed by arranging the genes in networks [7–9]. These
networks give an overview of the genes that are involved, as well as
their interactions, but not the dynamics of network changes that
result in phenotypic alterations like, for example, Th1 and Th2 cell
differentiation. Recent studies of the dynamics of Th1 and Th2 cell
differentiation using in silicomodeling have to some extent supported
a counter-regulatory role of Th1 and Th2 cells [10,11].
The gene networks used have been based on a relatively small,
though relevant, number of genes and interactions. In the present
work we applied an algorithm previously developed to analyze
large gene regulatory networks to perform in silico studies based on
a more comprehensive gene network model, which included a
larger number of genes [12,13].
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The network was constructed by combining text mining from
Medline (www.pubmed.com) based on seed genes and protein
interaction data, with manual annotation. The aim of our study was
to examine if the so-constructed network model was compatible
with a counter-regulatory role of Th1 and Th2 cells from healthy
humans as well as patients with different inflammatory diseases.
To achieve this we studied the effects of in silico knockouts on the
model dynamics [14], together with analyses of gene expression
microarray studies of T-cells from healthy controls and patients
with different inflammatory diseases.
Results
Definition of a network model of Th1 and Th2
differentiation
We defined a gene regulatory network (GRN) model of the
genes involved in Th1 and Th2 cell differentiation based on
manual annotation and automated data mining of Medline
abstracts. To ease inspection, this gene regulatory network was
organized into four layers according to the sub-cellular localization
of the genes (see Figure 1). Another reason for this exercise was to
enable the network for usage in agent-based models, as in [15].
The extracellular layer included cytokines (IL-7, TNFSF4, IFN-
c, IL-12 and IL-18), the antigens, as well as two membrane-
receptors expressed on antigen-presenting cells, namely CD80 and
CD86. The membrane layer consisted of the T-cell receptor and
cytokine receptors. The intracellular layer included signaling
molecules as well as transcription factors. Finally, an extra-cellular
layer consisted of autocrine cytokines (IL-4 and IFN-c) and
paracrine cytokines (IL-5 and IL-13).
Characterization of the attractors of the network
Gene regulatory networks (GRNs) can be represented as graphs
where nodes represent genes that are either active or inactive. The
state of the network is given by the combination of the activation
state of all genes. Starting from a certain state, the upcoming
configuration is computed by applying synchronously an updating
rule. In general, since the number of possible states is finite (i.e., qN
if N is the number of nodes, and q is the number of possible values
of a node), and the dynamics is deterministic, then from a given
initial state, the network can only evolve towards a limit cycle (i.e.,
attractor) of length one or more (up to qN{1).
In what follows, we go after Kauffman [15] by identifying the
attractors of the network dynamics as differentiation phases of the
cell, and the transformations between attractors as pathways of cell
differentiation.
Using the algorithm in [12] (briefly discussed in the Materials and
Methods section), we found that the GRN dynamics was character-
ized by four attractors, three of which corresponded to known Th
subsets, namely Th0, Th1 and Th2. The remaining attractor, which
we named ThX, contained both Th1 and Th2 genes (see Table 1).
The Th1 and Th2 attractors contained either Th1 or Th2
genes, an observation that was compatible with a counter-
regulatory role of Th1 and Th2 cells. For example, the Th1
attractor contained the transcription factor TBET, which has been
experimentally shown to induce the Th1 cytokine IFN-c and
inhibit the Th2 transcription factor GATA3, which, in turn,
induces the Th2 cytokine IL-4. Conversely, GATA3 inhibits
TBET and IFN-c. Thus, the two transcription factors TBET and
GATA3 play a key role in the counter-regulatory interaction
between Th1 and Th2 [5]. However, the mixture of Th1 and Th2
genes in the ThX attractor did not agree with a counter-regulatory
role between Th1 and Th2 cells. In particular, the state s1
contained both IFN-c and IL-4, while the state s3 contained both
TBET and GATA3 (Table 1). This suggested that the dynamics of
the network had an important role in regulating the balance
between Th1 and Th2 cells. This may correspond, in vivo, to the
situation in which antigenic stimulation may be temporary or
persisting, and result in different inflammatory responses [16].
In silico knockouts to model the dynamics of the network
We performed single gene in silico knockout experiments for all
genes in the network, in order to monitor the behaviour of the
attractors. In so doing, we distinguished two different settings,
corresponding to a different activation modality of the input nodes
(i.e., those contained in the yellow box of Figure 1): temporary-
stimulation and persisting-stimulation. In temporary stimulation we
examined the effects of an impulse-like stimulation of the input
genes, which means that those genes were considered active for a
short and transient period of time, and were set off thereafter. In
persisting stimulation instead, inputs were set on or off throughout
the observation period. Persisting stimulation is equivalent to
introducing self-loops on the input nodes of the GRN.
We computed the number of attractors for each single-gene
knockout and for both activation modalities. We found that the
median number of attractors per knocked out gene was 4 (range 3–
9) for temporary stimulation whereas it was 604 (range 322–1664)
for persisting stimulation, (Table 2).
Therefore, as a first observation we noted that, similarly to in vivo
stimulation, the network dynamics differed greatly between
temporary and persisting stimulation. Next, we proceeded to
examine the counter regulatory dynamics of the Th1 and Th2 cells.
This was done by testing the effects of in silico knockouts of intra-
cellular genes in the Th0, Th1, Th2 and ThX attractors. We started
by knocking out TBET and GATA3. If TBET and GATA3 were
counter-regulatory, knocking out TBET would be expected to result
in attractors mainly containing IL-4, but not IFN-c, while the
opposite would be expected after knocking out GATA3.
Firstly, we applied the temporary stimulation activation
modality (Figure 2). Knocking out TBET resulted in attractors
that contained both IL-4 and IFN-c, either IFN-c or IL-4, as well
as attractors without IL-4 and IFN-c. Knocking out IL-4 resulted
in attractors that contained either IFN-c or IL-4, as well as
attractors without IL-4 and IFN-c.
Author Summary
Different T helper (Th) cell subsets have an important role
in regulating the immune response in inflammatory
diseases. Th1 and Th2 cells are thought to counter-
regulate each other, and alterations in their balance result
in different diseases.This paradigm has been challenged by
recent clinical and experimental data. Because of the large
number of genes involved in regulating Th1 and Th2 cells,
assessment of this paradigm by experiments or modelling
is difficult. In this study, we combined novel algorithms for
network analysis, in silico knockouts, and gene expression
microarrays to examine if Th1 and Th2 cells had counter-
regulatory roles. We constructed a directed network model
of genes that regulated Th1 and Th2 cells through text
mining and manual curation. We identified four cycles in
the gene expression dynamics, three of which expressed
genes that corresponded to Th0 (Th1/Th2 precursor), Th1
and Th2 cells. The fourth cycle contained the expression of
a mixture of Th1 and Th2 genes. We found that neither in
silico knockouts of the Th1 and Th2 attractor genes nor
gene expression microarray data from patients and healthy
subjects supported a counter-regulatory role of Th1 and
Th2 cells.
Model and Dynamics of Th1/Th2 Cell Regulation
PLoS Computational Biology | www.ploscompbiol.org 2 December 2010 | Volume 6 | Issue 12 | e1001032
On the other hand, knocking out the same genes but applying
the persisting stimulation activation modality mainly resulted in
attractors containing both IL-4 and IFN-c (Figure 3).
For both temporary and persisting stimulation, the knockout of
other transcription factors that regulated Th1 and Th2 cells,
namely IRF4, MAF, NFAT, STAT1 and STAT6, also resulted in
attractors that contained IL-4 and IFN-c, either alone or in
combination. Thus, the balance between Th1 and Th2 cells was
regulated by several transcription factors, and not only by TBET
and GATA3.
To summarize, these findings were not compatible with a
strictly counter-regulatory role of neither TBET nor GATA3 or
any of the other transcription factors.
Analysis of relations between in silico and in vitro findings
in human T-cells in health and disease
We proceeded to examine how the in silico findings related to in
vitro studies of T-cells from healthy controls and patients with
different T-cell related diseases. We downloaded several sets of
gene expression microarray data from the public domain to test
Figure 1. Systemic view of the gene regulatory network model including relevant genes or transcription factors for Th1 Th2 cell
differentiation. Black edges depict positive regulation; red edges negative regulations.
doi:10.1371/journal.pcbi.1001032.g001
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whether Th1 and Th2 genes were inversely correlated in T-cell
related diseases.
If Th1 and Th2 cells are antagonists we would expect inverse
relations between genes in the Th1 and Th2 attractors. If so, the
expression levels of those genes would be negatively correlated.
Instead of this, we found a highly significant positive correlation
between the ratios of differentially expressed Th1-associated genes
and Th2-associated genes (Pearson correlation coefficient
r~0:799, p{valuev0:005).
Thereafter, we analyzed the correlations between all gene pairs
in the model that, based on the literature, were considered to
inhibit each other. This analysis showed that all gene pairs were
positively correlated but one (see Table 3).
This included the signature Th1 and Th2 genes TBET and
GATA3, which showed the most significant positive correlation
(r~0:81, pv10{14) as well as IFN-c and IL-4 (r~0:34, pv0:01).
Discussion
Because of the large number of proteins involved in Th cell
differentiation, alterations in the balance between those proteins
are not easily studied experimentally. Computational modeling
provides an attractive alternative to study the dynamics of Th1
and Th2 cell regulation and has previously been employed for this
purpose by us and others [10,11,17].
Such models have supported a counter-regulatory role of Th1 and
Th2 cells, but were based on a relatively limited number of genes and
did not include comparisons with biological data. In this report, we
aimed to examine if Th1 and Th2 cells were counter-regulatory by
combining modeling, in silico knockouts and gene expression
microarray analyses of human T cells in health and disease. We
constructed a network model of the proteins involved in Th cell
differentiation bymanual curation of proteins associated with Th1 and
Table 1. The attractors of the boolean network modeling
Th1/Th2 differentiation.
Attractor Active genes
Th0 None
Th1 IFN-c, IFN-cR, SOCS1, STAT1, TBET
Th2 GATA3, IL-13, IL-4, IL-4R, IL-5, IRF4, JAK1, JAK3, MAF,
NFAT and STAT6
ThX s1 : IFN-c, IL13, IL-4, IL-5, JAK3, NFAT and SOCS1
s2 : IFN-cR, IL13, IL-4, IL-5 and STAT6
s3 : GATA3, IL-4R, IRF4, MAF, SOCS1, STAT1 and TBET
ThX is the non-Th1-nor-Th2 attractor, consisting of a cycle composed by the
three states s1 , s2 and s3 .
doi:10.1371/journal.pcbi.1001032.t001
Table 2. Number of attractors in knock-out networks.
Temporary Stimulation Sustained Stimulation
knock-out gene attractors (static/dynamical) max attractors (static/dynamical) max
COT 4 (3/1) 3 1186 (898/288) 3
GATA3 3 (3/0) 1 322 (322/0) 1
IKBKB 4 (3/1) 3 594 (450/144) 3
IRAK 4 (3/1) 3 612 (452/160) 3
IRF4 9 (3/6) 5 604 (450/154) 5
ITK 4 (3/1) 3 1188 (900/288) 3
JAK1 4 (3/1) 3 594 (450/144) 3
JAK3 3 (3/0) 1 560 (432/128) 2
LCK 4 (3/1) 3 1187 (899/288) 3
MAF 4 (3/1) 3 594 (450/144) 3
NFAT 9 (3/6) 5 604 (452/152) 5
NFKB 4 (3/1) 3 594 (450/144) 3
NIK 4 (3/1) 3 1186 (898/288) 3
PI3K 4 (3/1) 3 1186 (898/288) 3
PLCPG 4 (3/1) 3 596 (452/144) 3
SHP1 4 (3/1) 3 594 (450/144) 3
SLP76 4 (3/1) 3 594 (450/144) 3
SOCS1 8 (5/3) 3 978 (594/384) 3
STAT1 7 (3/4) 6 1154 (482/672) 7
STAT4 4 (3/1) 3 612 (452/160) 3
STAT6 6 (3/3) 3 1664 (1088/576) 3
TBET 7 (3/4) 6 358 (322/36) 6
VAV1 4 (3/1) 3 595 (451/144) 3
ZAP70 4 (3/1) 3 1186 (898/288) 3
Number of attractors for the sustained and temporary stimulation; we give also the number of attractors which are of length one (static equilibrium) or of length greater
than 1 (dynamical equilibrium); moreover, we indicate the maximal length of attractors.
doi:10.1371/journal.pcbi.1001032.t002
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Th2 cells, and that had been identified as relevant through automated
text mining of the medical literature. This resulted in a significantly
more comprehensive model compared to previous versions.
Analysis of the dynamics of that model showed that it contained
four attractors, two of which corresponded to the Th1 and Th2
subsets. These contained the Th1 and Th2 specific transcription
factors TBET and GATA3, respectively. This was compatible with
a counter-regulatory role of these attractors. However, the fourth
attractor, which we named ThX, contained a mixture of Th1 and
Th2 proteins, including TBET and GATA3. This did not agree
with a counter-regulatory role of these transcription factors.
Furthermore, we extended our analysis by in silico knockout
experiments of TBET and GATA3. We reasoned that if the two
were counter-regulatory, then knocking out TBET would result in
attractors mainly containing IL-4, while knocking out GATA3
would result in attractors mainly containing IFN-c. Whereas this
was true for GATA3, it was not the case for TBET.
In fact, knockout of either TBET or the other Th1 and Th2
attractor proteins mainly resulted in attractors containing both
IFN-c and IL-4. Afterthat, we examined the expression of Th1 and
Th2 attractor genes in microarray studies of eleven T cell diseases,
namely autoimmune, infectious and oncological diseases.
In most of these, the expression of Th1 and Th2 attractor genes
increased concurrently, rather than in an opposing pattern.
Moreover, we found that genes in the network model that were
thought to inhibit each other based on experimental studies, were
in fact positively correlated. This was particularly true for TBET
and GATA3 which are thought to have a key role for the counter-
regulation of Th1 and Th2 cells. It is of note that the interactions
in the model were chosen based on experimentally validated
functions and interactions in Th cells. In many cases those
experiments were performed using polarizing cytokines and T cell
receptor stimulants. This is likely to result in more homogenous
Th cell responses than those seen in vivo. In the latter case Th cells
are activated by antigen-presenting cells which process the
antigens to peptides, subtle variants of which may have different
effects on Th cells. In addition, different doses and timing of
antigen exposure play an important role in the Th cell activation
and differentiation process. The effects of timing was reflected by
the results in our study; temporary and persistent stimulation had
profound effects on the network dynamics of these processes.
Moreover, the activation involves a complex and variable
mixture of proteins. Taken together, it is possible that this
complexity may result in a mixture of Th1 and Th2 cells
responses, rather than one of the two. The ThX attractor may
correspond to such a mixed or transitional response. This is
consistent with the increasing recognition that Th cell phenotypes
are plastic rather than discrete [2]. This recognition resulted from
experimental and clinical studies that show overlap between genes
considered to be Th1 and Th2 genes [18,19].
Our analyses of gene expression microarray data from human T
cells in health and disease lend further support to Th plasticity. From
an in vivo perspective, this plasticity allows fine-tuned responses to a con-
stant exposure of different antigens at different time points and doses.
It is also of note that in vivo Th1 and Th2 differentiation may be
affected by many other T cell subsets, of which an increasing
number have been recognized. Moreover, epithelial cells, mast
cells and eosinophils release cytokines that affect the differentiation
process. Ideally, simultaneous analysis of networks representing
those cells and subsets would yield an understanding not only of
Th1 and Th2 cells, but comprehensive models of the cellular
networks that underlie immunological diseases. Improved meth-
Figure 3. Number of attractors as the result of in silico knockout
experiments, in the persisting stimulation activation modality.
Stacked bars represent the percentage of attractors expressing
combinations of IL-4 and/or IFN-c.
doi:10.1371/journal.pcbi.1001032.g003
Table 3. Results of Pearson’s correlation test of inhibitory
gene pairs.
Gene Pair p-value correlation r
GATA3 - TBET v10{14 0:81
SHP1 - JAK1 v10{9 0:69
IL-4R - IL18R v10{5 0:56
SOCS1 - IL-4R v10{11 0:76
SOCS1 - JAK3 ~0:9341 {0:01
STAT6 - STAT4 v10{5 0:56
IFN-c - IL-4 ~0:00702 0:34
doi:10.1371/journal.pcbi.1001032.t003
Figure 2. Number of attractors as the result of in silico knockout
experiments, in the temporary stimulation activation modality.
Stacked bars represent the percentage of attractors expressing
combinations of IL-4 and/or IFN-c.
doi:10.1371/journal.pcbi.1001032.g002
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odologies, such as single cell RNA sequencing may make such
models feasible in the near future.
A limitation is that our model is that the underlying biological
data is mainly qualitative. Thus, the model is based on
synchronous updating and does not take into account quantitative
or time-dependent changes. Others have shown that asynchronous
updating may have different effects on attractors [20–22]. An
interesting future research direction is to perform time series
experiments of Th1 and Th2 cells using gene expression
microarrays. Using such data it may be possible to improve our
model both with regards to quantitative and time-dependent
changes and also make predictions which can be validated with
other biological methods, such as measuring Th1 and Th2
cytokines on the protein level.
In summary, our findings, both based on in silico modeling and
analysis of T cells from human diseases agree with Th1 and Th2
cells having complex and possibly synergistic, rather than counter-
regulatory roles.
Materials and Methods
Identification of genes for the network model of Th1/Th2
cell differentiation
We employed a step-wise procedure to define the set of relevant gen-
es for the differentiation of Th cells into the Th1 and Th2 phenotypes.
Firstly, we identified two different sets of genes as a primary
source: i) 17 genes from a previous network model [10]; ii) a set of
17 genes determined in a gene expression microarray study of
polarized Th1 and Th2 cells by [6]. All these 34 genes were used
as seed genes. Then we retrieved the first order neighbors of these
seed genes and their connections in the BioGrid database (www.
biogrid.org). Successively, the connection among the proteins of
the first order neighbors were retrieved. Among all the genes
retrieved thus far, we selected only those associated to the Gene
Ontology term (www.geneontology.org) ‘‘T cell differentiation’’.
More specifically, the genes co-cited in the millions Medline
abstracts together with this term were retrieved. This resulted in a
set of 403 genes, that was further slimmed down and used to
construct a manually annotated directed graph of gene interac-
tions relevant for Th1 and Th2 cell differentiation. This was made
by using the T-cell receptor pathway in the KEGG database as a
template (www.genome.jp/kegg/pathway.html). Genes that were
part of that pathway and had well-characterized and experimen-
tally verified functions relevant for Th1 and Th2 cell differenti-
ation were selected for the final network model. A detailed
description of each interaction in the network, together with 126
supporting references is given in Text S1. It is also of note, that the
network model was independent of the gene expression micro-
array experiments, which are described below (none of the
published abstracts pertaining to those experiments contained co-
cited genes that were included in the model).
Boolean networks as a model of Genetic Regulatory
Networks
Given a GRN, the number of attractors of the network
dynamics is, in general, not effectively computable since the
number of states of the network grows exponentially with N. It is
not even possible to effectively calculate the initial states of the
network that will eventually fall in the basin of attraction of a
specified limit cycle. When the number of genes is large, the
explicit computation of the dynamics becomes impractical as the
number of states the network can assume increases exponentially
with the number of nodes. In the worst case the algorithm needs to
store the complete description of the state transition graph and
therefore the exhaustive study is feasible only when the number of
nodes is small [10,23]. Just to give an idea, for a network with
N~40 nodes, one needs about 6 Terabytes to store the state-
transition graph of the network. In our case, with N~51, it would
require about 7 Petabytes of storage.
In recent studies, formal methods such as bounded model-checking
technique or reduced order binary decision diagrams have been employed
in the study of attractors of Boolean and multivalued networks, see
Dubrova et al., Garg et al., and Chaves et al. [12,21,24–26]. These
formal methods have a potential to handle large networks. In
particular we used Dubrova’s algorithm based on a solver for the
satisfiability problem (SAT) which from the logical structure of the
network infers the possible attractors. In simple words, the network
can be seen a Boolean circuit and its attractors can be computed
by using methods and largely optimised algorithms coming from
modeling of Very Large Scale Integration (VLSI) circuits.
What is special about formal methods approach is that it
enables to find attractors of large networks. The idea behind the
search algorithm is that, by using symbolic computation, it is
possible to unfold the dependencies between nodes that are linked
together and to compose the update function as a relation among
the states (activation/inhibition) of the genes/nodes. Then the
algorithm uses the SAT solver to determine the values of the states
that evaluate to true the relation. This process is then repeated until
all attractors are identified.
We specified the network as the set of rules R1,R2, . . . ,RN , each
one representing the activatory or inhibitory relation between genes.
For example, if rule R stems for the activation of gene g, and is deter-
mined by the activators x1,x2, . . . ,xn and inhibitors y1,y2, . . . ,ym
(activators and inhibitors are generically called regulators), then it can
be written as R :~x1, . . . ,xn,{y1, . . . ,{ym?g, where conven-
tionally the subset of inhibitors are tagged with a minus sign.
Analogously to [10,12], the time is discrete and the activation
states of the genes are changed simultaneously (i.e., synchronous
update). At each time step t, the value of the gene g is denoted by
the same gene name g tð Þ. The successive value of gene g tz1ð Þ is
g tz1ð Þ~ _n
i~1
xi tð Þ
 
^ : _m
j~1
yj tð Þ
 
ð1Þ
where _,^ and : denote the logical operators and, or and not
respectively. The rule in Equation 1 states that for a gene to be
activated, at least one activator and no inhibitors must be active
[10 12, 27].
In our specific case we had a set of 43 rules involving 51 genes,
that was the result of data mining andmanual annotation. These are
listed in Table 4. The network so specified was compiled in other
formats, in particular GML (Graph Modeling Language), which is
used in several applications specialized in graphical layout, and
CNET which is the input form accepted by the algorithm to
compute the attractors. Whereas the GML output was based simply
on activation/inhibition network links, in the CNET format we had
to specify the updating function for each node.
The last part of this work was the systematic characterization of
the networks obtained by knocking out genes one at a time. As a
consequence of these in silico knockout experiments we anticipated
two results: a) to identify the set of genes which are pivotal to the
Th1/Th2 differentiation; b) to spot subsets of co-expressed genes
belonging to the attractors, since from analysis of microarray data
we expected these genes to be correlated.
Changes in the set of the attractors were used to highlight
relevant nodes. As a first approximation, differences in the mere
number of attractors were considered; if a node did not affect the
number of attractors, then from the point of view of the dynamics
it was considered irrelevant.
Model and Dynamics of Th1/Th2 Cell Regulation
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Compilation and analysis of gene expression microarray
data
To examine whether Th1 and Th2 gene activation patterns
denoted two opposed pathways, gene expression data were
downloaded from Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/). Datasets were selected based on the criteria that
they i) measured mRNA expression from CD4+ cells from healthy
controls or patients with T-cell related diseases (e.g., SLE) and ii) that
there were at least 5 samples per disease or per controls, (Table 5).
Differentially expressed genes between patients and controls in
each disease were determined using the unpaired Student’s t-test.
Genes with a significance p{valuev0:05 were considered
differentially expressed.
In order to examine if the differentially expressed genes in the
Th1 and Th2 attractors were negatively or positively correlated we
performed the following analyses: for each disease, the ratio
between differentially expressed genes in the Th1 attractor and all
genes in the Th1 attractor was computed. This analysis was
repeated for the Th2 attractor genes. It resulted in a list of ratios
for each attractor and for each disease. The Pearson correlation
coefficient between those ratios was then computed.
To test if gene pairs in the network model that had counter-
regulatory relationships were also negatively correlated, micro-
array data belonging to healthy controls in each dataset was
pooled and Pearson correlation coefficients were calculated for all
the gene pairs with counter-regulatory relationships.
Supporting Information
Text S1 References for interactions. In this document we
present references supporting interactions introduced in our
model network.
Found at: doi:10.1371/journal.pcbi.1001032.s001 (0.12 MB PDF)
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Table 4. Specification rules for activation/inihibition links of
the network in Figure 1.
IRF4, NFAT, MAF, GATA3 ? IL-13
IRF4, NFAT, MAF, GATA3 ? IL-5
IFN-cR, -GATA3, STAT1 ? TBET
IL-7R, TBET, STAT4,STAT1,IRAK ? IFN-c
STAT6 ? MAF
STAT6, -TBET ? GATA3
IL-7 ? IL-7R
IL-18, -IL-4R ? IL-18R
IL18R ? IRAK
IFN-aR1, IFN-cR ? STAT1
IFN-a ? IFN-aR1
IFN-c ? IFN-cR
IL-4, -SOCS1 ? IL-4R
IRF4, NFAT, MAF, GATA3 ? IL-4
CD80 ? CTLA4
CTLA4 ? SHP1
CD45, CD4 ? LCK
TCR, CD3, -SHP1,LCK ? ZAP70
ZAP70 ? SLP76
LCK ? VAV1
CD28, VAV1, SLP76 ? ITK
ITK ? PLCPG
ANTIGEN ? CD4
ANTIGEN ? TCR
ANTIGEN ? CD3
ANTIGEN ? CD45
TNFSF4 ? TNFRSF4
-IFN-cR, TNFRSF4, IKBKB ? NFKB
STAT6, NFKB ? IRF4
CD28, TNFRSF4, PLCPG, IRF4 ? NFAT
CD28, ICOS ? PI3K
PI3K ? AKT1
AKT1 ? COT
COT ? NIK
NIK ? IKBKB
CD86 ? CD28
IL-4R, -SHP1,-SOCS1 ? JAK1
IL-4R ? JAK3
IFN-aR1, JAK1,JAK3 ? STAT6
IL12R, IFN-aR1, -STAT6 ? STAT4
IFN-cR, STAT1, TBET ? SOCS1
IL-12 ? IL-12R
TNFSF4 ? ICOS
doi:10.1371/journal.pcbi.1001032.t004
Table 5. Gene expression microarray datasets downloaded
from the Gene Expression Omnibus repository.
GEO Accession Number Disorder
GSE4588 Systemic Lupus Erythematosus (SLE),
Rheumatoid Arthritis (RA)
GSE6740 HIV
GSE8835 B cell chronic lymphocytic leukemia (CLL)
GSE9927 Type I HIV (HIV-I)
GSE10586 Type 1 Diabetes (T1D)
GSE12079 Hypereosinophilic syndrome
GSE13732 Clinically Isolated Syndrome - Multiple Sclerosis
GSE14317 Adult T-cell leukemia/lymphoma (ATL)
GSE14924 Acute Myeloid Leukaemia (AML)
GSE17354 Adenosine deaminase (ADA) - Severe combined
immunodeficiency (SCID) (Therapy treated)
doi:10.1371/journal.pcbi.1001032.t005
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Abstract
Background: The immune contribution to cancer progression is complex and difficult to characterize. For example
in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the
tumor microenvironment. Profiling the immune component of tumors may facilitate the characterization of the
poorly understood roles immunity plays in cancer progression. However, the current approaches to analyze the
immune component of a tumor rely on incomplete identification of immune factors.
Methods: To facilitate a more comprehensive approach, we created a ranked immunological relevance score for all
human genes, developed using a novel strategy that combines text mining and information theory. We used this
score to assign an immunological grade to gene expression profiles, and thereby quantify the immunological
component of tumors. This immunological relevance score was benchmarked against existing manually curated
immune resources as well as high-throughput studies. To further characterize immunological relevance for genes,
the relevance score was charted against both the human interactome and cancer information, forming an
expanded interactome landscape of tumor immunity. We applied this approach to expression profiles in
melanomas, thus identifying and grading their immunological components, followed by identification of their
associated protein interactions.
Results: The power of this strategy was demonstrated by the observation of early activation of the adaptive
immune response and the diversity of the immune component during melanoma progression. Furthermore, the
genome-wide immunological relevance score classified melanoma patient groups, whose immunological grade
correlated with clinical features, such as immune phenotypes and survival.
Conclusions: The assignment of a ranked immunological relevance score to all human genes extends the content
of existing immune gene resources and enriches our understanding of immune involvement in complex biological
networks. The application of this approach to tumor immunity represents an automated systems strategy that
quantifies the immunological component in complex disease. In so doing, it stratifies patients according to their
immune profiles, which may lead to effective computational prognostic and clinical guides.
Background
Although a link between the immunity and cancer was
observed almost 150 years ago [1], the exact nature of
the relationship has been developed and debated
through several stages of complexity. In recent years, it
has been established that the immune system plays cru-
cial roles in tumor development [2], and indeed on
patient survival for various cancers [3-7]. Due to a lack
of comprehensive analytical approaches, molecular char-
acterization of the roles of the tumor immune compo-
nent has been somewhat difficult to elucidate on a
genome-wide scale.
Current strategies to identify the immune component
of tumors tend to employ incomplete manual efforts
that do not grade the immune genes. Indeed, even the
very definition of an immune gene is unclear, as several
interconnected subsystems comprise the totality of
immunity. In addition, an analysis of the molecular
interactions linked to tumor immunity is usually limited
to a pathway-centric paradigm, which is often hindered
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by the complexity in which immune pathways are
entangled in signaling crosstalk [8]. These challenges are
further complicated during cancer progression by the
migration of immune cells into unique microenviron-
ments, and by the altered expression of immune genes
intrinsic to the tumor. Consequently, as in a tumor gene
expression profile, it is not trivial to grade the immune
component or identify its related molecular networks.
Multidisciplinary and integrated strategies that handle
these and other complex challenges of tumor immunity
are increasingly sought after [9-16]. With recent
advances in genomics, and increased amounts of latent
detailed knowledge in the medical literature, computa-
tional approaches can now be developed to study the
importance of immune genes and their networks of
interactions linked to cancer progression.
Consequently, we have devised a strategy that assigns
a ranked immunological relevance score to all human
genes for the purpose of profiling the immune compo-
nent of tumor gene expression. Coupling text mining to
information theory, this approach charts immunological
relevance onto the human interactome. To apply this
strategy in a cancer specific manner, we analyzed mela-
nomas. We first identified immunological signatures
that were differentially regulated in the progression
from primary stages of skin cancer through to metas-
tases [17]. Survival data from a set of advanced stage
melanoma patients were also analyzed, to assess the link
between immunological relevance of genes in expression
profiles and clinical outcome [5,18].
Our computational approach to assign immunological
relevance to genes was benchmarked against manual
efforts that identify immune genes, and the strategy was
shown to substantiate the performance of existing
immunological grading systems. Furthermore, it identi-
fied the ranked immunological components of the
expression profile of a tumor with its associated net-
works of interactions. This informative grading of the
magnitude of the immune component from patient gene
expression profiles may serve as a computational diag-
nostic and prognostic guide to assess the aggressiveness
of a given tumor.
Results
An information theoretical approach to assign
immunological relevance to genes
A comprehensive list of 1921 immunology terms was
compiled by manual selection of the most relevant
terms from the standard biomedical vocabularies of
Medical Subject Headings (MeSH) in Medline and the
Gene Ontology (GO) controlled vocabulary (see Meth-
ods: “Defining the dictionary of terms for immune and
neoplasm relevance”). This broad set of terms was col-
lectively considered to be the immunological symbols of
communication stored in the over 20 million articles of
the biomedical literature (Additional file 1). Using estab-
lished text mining procedures [19] (see Methods:
“Extraction of human genes, immune and neoplasm
terms from Medline”), we used these terms and their
relationships to gene citations in Medline by capitalizing
on the universal feature of coded information, present in
all forms of communication. By this, it is implied that
immune relevant genes have a level of immune informa-
tion content quantified using this combined set of
immune terms in Medline, which is greater than that of
genes that play a lesser role in the immune system.
Information theory calculations were used to measure
the size of the immunological message stored for each
human gene with respect to these terms. The probabil-
ities in the information theory calculations were defined
through the frequency by which a given gene is cited
with a given immune term relative to the number of
times the immune term is cited in Medline among all
human genes with that term. This measure of immune
information content for a gene may be biased by the
higher frequency of certain genes being associated over-
all with the sources of the immune terms, i.e. the popu-
larity of a gene among all terms in the biomedical
vocabularies. This bias was corrected for using a method
in information theory known as the Kullback-Leibler
(KL) divergence (see Methods: “An immunological and
cancer relevance score for all human genes using infor-
mation theory and text mining”). The KL score for all
human genes was defined as the “immunological rele-
vance” for a gene and termed as such throughout this
study (Additional file 2). A similar strategy was also
applied to a manual selection of 562 cancer disease
terms to determine a genome-wide cancer relevance
score for every human gene.
Benchmarking of the immunological relevance score and
the extension of immune gene resources
In order to benchmark this immunological relevance for
genes, we compared the score against a set of validated
immune resources. We utilized gene sets from six
manually curated immune efforts (see Methods: “Collat-
ing manually curated immune relevant gene sets”) that
contain independently annotated genes relevant for var-
ious aspects of immunity. There were a total of 4833
genes in this integrated set, which had a heterogeneous
distribution across the six resources, in that only 82
core immune genes were common to all databases.
Many genes in each resource were shared with merely
one of the other resources, and few genes were unique
to an individual resource (Figure 1). The benchmarking
of the immunological relevance score against this set of
manually curated immune resources is presented in
Figure 2A. The average immunological relevance score
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over all genes in each database was determined, com-
pared against each other and the genes not manually
curated by these resources. The Immunome [20] ranked
the highest among the six manually curated resources in
terms of immune information content, reflecting its
focus on collating genes enacting functions specific to
immune cells. When measuring the immunological rele-
vance of all genes assigned a name by the Human Gen-
ome Organization (HUGO) and not catalogued in any
of the immune resources, the average approaches zero.
The frequency distribution of immunological relevance
for all human genes assigned a name in HUGO shows a
sharp decline from high to low immunological relevance
(Figure 2B), revealing distinct categories of immune and
non-immune genes. Moreover, the top ranked genes in
the non-curated list represent novel candidates for entry
in immune resources (Additional file 3). To assess
further the benefit of assigning an automatic immunolo-
gical relevance score to genes, the integrated set of
manually curated genes was compared against two large
scale studies that have characterized the human inflam-
matory response: (1) the endotoxin response network
from gene expression profiling in human leukocytes
[21], and (2) the inflammation assembly, which consists
of genes detected in genetic variants in inflammatory
pathways [22]. The endotoxin response network and
inflammation assembly had 66% and 13% non-overlap-
ping genes with respect to the manually curated
resources. The non-correspondence of these six expert
resources with large-scale experimental efforts partly
indicates the specialized nature of some of these
resources and partly may indicate potential in further
management of immune knowledge from expert cura-
tors. It may also illustrate that there could still be more
genes to be implicated in human immunity that are as
yet uncharted.
The interactome landscape of immunological and cancer
relevance
An affirmed realization from the post genomic era is that
no gene functions in isolation, but rather is embedded in
a complex network of interacting molecules [23]. Our
strategy to profile the immune component of tumors
would therefore benefit from an analysis of how immu-
nological relevance relates to the position a gene occupies
in complex cellular networks (in this case an integration
of three human interactome databases, see Methods:
“Constructing a validated human interactome & network
analysis”). The creation of a validated and ranked score
of a gene’s immunological relevance allowed us to chart
this score in a landscape setting against cancer relevance
and the positional importance (centrality) of a gene in
the interactome (Figure 3). Centrality is a class of net-
work measurements used to determine the relative
importance of a gene in cellular networks. We analyzed
five different centrality measures the principal of which
being connectivity (i.e. number of interactions per gene).
Genes from the six manually curated immune resources
on average had a higher connectivity relative the entire
interactome (data not shown). Interestingly, increasing
Figure 1 Heterogeneous distribution of genes in immune databases and an incomplete catalogue of immune knowledge. (A) Bar chart
depicting the shared gene distribution of the immune resources. 82 of the total integrated set of 4833 genes are common to all 6 manually
curate resources (orange colored bar). Few genes were unique to an individual database, ranging from a minimum of two for “Immunome” and
122 for the “Innate”. (B) An approximation using a Venn Euler diagram illustrates the heterogeneous overlap among the different databases. The
Innate database being the largest resource has the largest intersections. The septic shock resource has smaller overlaps with the others (with the
exception of Innate) highlighting its focus on collating genes related to the response to bacterial toxins during septic shock.
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immunological or cancer relevance showed no strong
correlation with connectivity or to any of the four other
network centrality measures (Additional file 4). The
immune and cancer genes harboring the highest connec-
tivity (network hubs) raise the average, and were
unevenly distributed across the heterogeneous interac-
tome landscape (Figure 3). This analysis allowed the
detection of scattered peak regions whose genes play dri-
ver roles in propagating signals with importance to
tumor-immune crosstalk. The classical coordinator of
Figure 2 Benchmarking of immunological relevance scores against manually curated immune resources. (A) The mean immune score
for each database is depicted in the bar chart. The core immune genes are those 82 genes that are common to all immune resources and have
a significantly larger amount of information content in comparison to each of the individual immune resources. (B) The frequency distribution of
all HUGO name assigned genes reveals a sharp decline in immune relevance across the genome.
Figure 3 The tumor-immunity interactome landscape. A three-dimensional surface plot representing the landscape of degree centrality
(connectivity) of the interactome in the context of immune and cancer relevance: All axes are on the log scale and values above one on the
log scale were considered high in terms of immune and cancer relevance. The consideration of one on the log scale as high in terms of
immune relevance is made on the basis of the average immune scores for the expert sources ranging from 1 bit and above (see Figure 2). The
color scale in the heatmap is representative of the connectivity of each gene in the human interactome. That which is apparent is the distinct
areas of scattered high and low connectivity for genes in the cancer-immune landscape. The underlying data for this plot is detailed in
Additional File 5.
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tumor-immune interactions, IFNG, and various T-cell
markers were among the highest ranked in this high peak
category, as displayed in the underlying interactome
landscape data in Additional file 5. We also observed a
high degree of correlation (0.75 Spearman’s coefficient)
between immunological and cancer information content
across the genome.
Immunological comparisons of normal tissues and
robustness of tissue specific immune interactions
As gene expression profiles of both normal and tumor
tissue represent the combined signal of all cell types pre-
sent in a sample: a global evaluation of the
immunological component of normal tissue profiles was
attempted, prior to the particular goal of quantifying
such for tumors. For this purpose, we calculated the pair-
wise fold change comparisons of the differentially
expressed genes among the 79 tissues profiles from the
SymAtlas project [24] and the average immunological
relevance score for those differentially expressed genes
(shown in heatmap Figure 4A). A gene was considered
differentially expressed if it had greater than a two-fold
difference in expression between the two tissues under
comparison. The pairwise comparisons revealed hetero-
geneous differences in immunological components
among normal tissues (see heatmap in Figure 4A). The
Figure 4 Immunological components of normal tissue. (A) Heatmap of the immunological gene expression fold-change comparisons among
the 79 tissues from the SymAtlas [24]. This matrix displays the average immune score from those genes that contribute to greater than 2 times
fold change difference between each tissue’s pairwise comparisons. This combination of expression profiling and immunological grading detects
a heterogeneous difference in the immunological components between tissues in a global manner. Both the X and Y-axis are numerical index
of the 79 tissues (the mapping of this index to tissue name is listed in Additional File 8). With respect to the robustness of immune genes in the
interactome : (B) Tissue specific interactome networks for Wholeblood (eccentricity centrality = 0.67) and Heart (eccentricity centrality = 0.72).
The difference in the average eccentricity value is only marginally visible by eye as evidenced by a lower symmetry of the Heart network (the
same transparent circle drawn on top of the two networks displayed by means of the same algorithm using the software yEd).
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comparison, for example, between CD4 and CD8 positive
T-cells from the tissue SymAtlas [24] had the largest
immunological difference (see heatmap in Figure 4A, col-
umns No 48 and 50 for CD4 and CD8 respectively). The
procedure used to determine the differentially expressed
genes is detailed in the Methods section entitled: “Micro-
array gene expression analysis and a composite expres-
sion and immunological relevance score”.
In order to characterize the differences in the immuno-
logical component of these tissues from the perspective
of the interactome, we used tissue specific networks pre-
viously determined for the SymAtlas tissue profiles [25].
In addition to connectivity, we calculated four other net-
work centrality measures on each of these tissues net-
works (betweeness, eigenvector, closeness and
eccentricity). To test if any of these centrality measures is
a discernible property more specific to immune cells, we
implemented K-means clustering on all five of the cen-
trality measures across the tissues. Eccentricity was the
only measure that classified the tissues in a biological
meaningful manner (with K = 9 clusters), in that closely
related tissues clustered together (e.g. neurological or
immune related tissues, see cluster groups in Additional
file 6). Moreover the distribution of the gene eccentricity
centralities for each of the tissue interactome networks
showed that immune cells had the lowest average eccen-
tricity values (see brown lines, peak value at 0.63 in
Figure 5). Leukocytes clustered into three classes, with
CD4 and CD8 positive T-cells grouped with wholeblood,
lymphoblast precursors into their own separate class, and
the remainder of the blood cells profiled (including den-
dritic cells and NK cells) into a third class (Figure 5 and
cluster groups in Additional file 6). The interaction net-
work of a tissue (wholeblood) from the former immune
cluster was significantly different from a random network
(Wilcox rank, p-val of 0.01) and illustrated graphically in
a comparison of this network to that of a non-immune
tissue (heart) in Figure 4B. The difference in average
eccentricity values between these two tissues is margin-
ally visible in Figure 4B. As immune cells express more
immune relevant genes and their eccentricity measures
relate to shorter network distance, overall this tissue
group clustering suggests that immune genes have more
robust connections in the interactome.
Figure 5 Normalized frequency distribution of tissue specific eccentricity. The distribution (i.e., normalized frequency) of the gene
eccentricity centralities for each of the tissue specific interactome networks (the same 79 human tissues profiled in Figure 4). Different network
groups can be classified on the basis of the maximal value of the eccentricity distribution. Some network groups have a differential maximal
value of distribution, and immune cells had the lowest values. The lower eccentricity values of immune cells reinforce the postulate that
immune genes have robust reach throughout the human interactome. Equal colors in the legend correspond to equal maximal values of the
normalized eccentricity.
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Immunological networks signatures and clinical outcome
from expression profiles in melanoma patients
We next extended the principle of tissue expression pro-
filing of immunological signatures in normal tissue to
that of expression of normal skin, primary skin tumors
and metastatic melanoma [17]. From the pairwise com-
parison of genes with a greater than two-fold change in
expression across these different tissue states, we aver-
aged the immunological score for those genes differen-
tially expressed (> 2 times fold change) and examined
how this score differed across the various expression
profiles (see Figure 6). Using this average immunological
score, we detected clear differences in the stages of pro-
gression and related these comparisons to their immune
subnetworks from the interactome (see Figure 6). There
was a particularly high immunological difference
between normal melanocytes and both metastatic and
primary melanoma and between normal skin and both
metastatic and primary melanoma. The magnitude of
the immune component difference between metastatic
and normal melanocytes is depicted in Figure 6, along
with a related immunological subnetwork of interac-
tions. This network signature shows strong T-cell
activation as well as diverse tumor associated chemokine
and cytokine activity. There was, however, a much smal-
ler immunological difference between metastatic mela-
nomas and primary melanoma compared to that of
normal melanocytes (Figure 6). This suggested that the
framework could detect putative signatures of adaptive
immunity in mediating transitions at early stages of pro-
gression in these patients. The observation that the
highest ranked immune genes in these comparisons,
CD4 and CD8, were upregulated in primary melanoma
and metastasis compared to normal melanocytes signif-
ied early and enduring T-cell infiltration. In this com-
parison, immunological scoring also prioritized markers
of innate immune cells such as PECAM and CD14
among others, accompanied by cytokines of inflamma-
tory responses (IL15, IL7, IL18, IL1A, IL8). Interestingly,
there was also high ranking of an early Th2 tumor-pro-
moting environment demonstrated by presence of the
IL13RA2 gene and the Th1 inhibiting cytokine IL10.
The smaller amount of immunological information cap-
tured in the comparison of primary to metastatic mela-
noma (Figure 6) was attributable not to high scoring
leukocyte or inflammation markers, but by upregulation
Figure 6 Comparison of the immunological component of skin cancer and states of melanoma progression. A heatmap of the average
bits of immune information of the differentially expressed genes (> 2 times fold-change) among the pairwise comparisons of normal skin and
skin cancer states. The labels from the left to right columns refer to normal skin tissues: ("Normal”), normal melanocyte ("Melanocyte”) and then
various states of skin cancer: primary melanoma ("Primary”), squamous cell carcinoma ("Squamous”), basal cell carcinoma ("Basal”), in-situ
melanoma ("In Situ”) and metastatic melanoma ("Metastatic”). Distinct differences in the immunological component of the various skin cancer
and normal states are detected. We have focused here as an example, on the comparison between metastatic melanoma and normal human
melanocytes. A subnetwork module from the interactome landscape of those genes with high immunological relevance is displayed.
Upregulated genes are color-coded red and downregulated genes are color-coded green in this network. The size of a gene is proportional to
the immunological relevance of the gene. There is clearly increased T-cell activity such as the presence of increased expression of CD8, CD4 and
CD3 T-cell markers. This coincides with upregulation of key chemokine and cytokine interactions.
Clancy et al. BMC Medical Genomics 2011, 4:28
http://www.biomedcentral.com/1755-8794/4/28
Page 7 of 14
of immunogenic melanoma antigens (MAGEA2/3) and
downregulation of apoptosis inducing S100A8/9 cyto-
kines. Summarized gene lists of the top ranked immu-
nological transitions of normal skin, primary and
metastatic melanomas are presented in Table 1. In-situ
melanoma (MIS) compared to squamous cell carcinoma
(SCC) held the highest immunological difference among
all the state comparisons (Figure 6). Some of the top
ranked immune genes in that comparison included
upregulation in SCC relative to MIS of the chemokine
CXCL13 and downregulation of the innate immune
gene LTF
A composite gene expression and immunological rele-
vance score was used to grade each patient expression
profile and find clinical trends to immunological gene
signatures (see Methods: “Microarray gene expression
analysis and a composite expression and immunological
relevance score”). Although the Riker et al. study was not
accompanied by clinical outcome data, there was a trend
in two patients with giant primary melanomas (Breslow
thickness of 90 mm) and downregulation of highly rele-
vant immunological genes (p-val, 0.02) compared to 12
other patients with primary melanomas. Using this com-
posite grade, we examined the immunological differences
in the outcome, as well as in other clinical features of 57
patients that had reached metastatic melanoma at stage
IV [18] and 38 patients at stage III (Bogunovic et at,
2009). Notably, there was a significant association (p-val,
0) with the “high-immune” group of patients as anno-
tated by Jonsson et al (as identified by one term, chosen
a-priori). Similarly, the strategy detected downregulated
highly relevant immunological genes in the patient group
that fell into the “proliferative” group of patients (p-val,
0). An upregulated immunological trend was detected in
patients that had favorable survival (p-val, 0.1) and was
more significant (p-val, 0.02) in those patients categor-
ized with “brisk” immune phenotype (infiltration of CD3
positive lymphocytes). The patient group with NRAS
mutations (Q61L) had a correlation with downregulated
immunological signatures (p-val, 0.007), hence classifying
a group of patients with immune signaling interactions
acting downstream of this oncogenic mutation. Patients
with hypermethylation of the p16INK4A promoter had
trends towards upregulation of genes with high
Table 1 Top ranked immunological transitions of melanoma progression
Gene comparison conditions Highest graded immune genes Significance to Melanoma progression
Upregulated (> 2fc) in both primary and
metastatic melanoma compared to normal
melanocyte (Immunological relevance score for
each gene (KL) > 11 bits).
CD4, IL10, CD8A, CD40, IL15, IL7, IL18,
TNFSF13B, PTPRC, IL13RA2, IL1A, PECAM1,
C5AR1, CD86, ISG20, IL18R1, CD14, ITGB2,
ADORA3, FCGR3A, CCL2, IL8, CCR5, FCGR3B
Signatures of T-cell infiltration, T-cell activation
and the inflammatory response. Inclusive of the
Th1 inhibiting cytokines
Downregulated (> 2fc) in both primary and
metastatic melanoma compared to normal
melanocyte (Immunological relevance score for
each gene (KL) > 0.5 bits).
MME, IL24, DPP4, CYGB, MSC, SLC7A8 Regulation of extracellular matrix (ECM)
remodeling, through proteolytic enzymes, and
amino acid transporters
Upregulated (> 2fc) in primary melanoma
compared to normal melanocyte. Not subject to
>2fc in metastasis (Immunological relevance
score for each gene (KL) > 2 bits).
IL5, TNF, IL1RN, DARC, HLA-DRB4, CFP, PTPN6,
CD1B, ELA2, IL17B, ATP8A2, SLPI, CD27, STAT4,
CDA, IL26, DEFB4, NFKBIA, HRH1, XCL1, DEFB1,
PDPN, CTSG, SDC1, GATA3, MSMB, CD24,
POU1F1, PRDM1, EBF1
Cytokine activity that is pro-survival and towards
ECM remodeling. Increased transcriptional
activity related to T-cell activation in the primary
tumor. Increased presence of MHC class II
markers.
Downregulated (> 2fc) in primary melanoma
compared to normal melanocyte. Not subject to
>2fc in metastasis (Immunological relevance
score for each gene (KL) > 1 bit).
BAX, TNFRSF10B, SV2A Down-regulation is indicative of p53
dysfunction and transduction of apoptosis
signals. Overall leading to pro-survival in the
primary tumor compared to normal cells
Upregulated (> 2fc) in metastatic melanoma
compared to normal melanocyte. Not subject to
>2fc in primary. (Immunological relevance score
for each gene (KL) > 1 bit).
CCRL2, HLA-DRB1, MDK, C4A, CD55, CD80,
FCGR1A, KLRC4, ICAM1, SPI1, HCST, PPBP,
FCGR2C, GPR160, CXCL16, FOS, SERPINA1
Mediators of inflammation, angiogenesis, cell
growth, and cell migration. Also present are
signals of humoral immunity in the form of T-
cell activation and B-cell development genes
Downregulated (> 2fc) in metastatic melanoma
compared to normal melanocyte. Not subject to
>2fc in primary. (Immunological relevance score
for each gene (KL) > 1 bit).
KIT, IRF4, MLANA, MMP1 Down regulation of cell adhesion, differentiation
factors and regulators of the innate and
adaptive immune systems. Possibly promoting
the metastatic phenotype
Upregulated (> 2fc) in metastatic melanoma
compared to primary (Immunological relevance
score for each gene (KL) < 1 bit).
MAGEA3, CSAG2, MAGEA2, GAGE1, MAGEA12,
GAGE3, FKBP10
Eliciting immune T cell activation in metastatic
tumors, as a consequence of being expressed
particularly in the metastatic stages, while
having very restricted expression in normal cells
Downregulated (> 2fc) in metastatic melanoma
compared to primary (Immunological relevance
score for each gene (KL) > 1 bit).
S100A9, S100A8, SLPI, DEFB4, DEFB1, MSMB,
CD24, DEFB103A, COL17A1
Altered matrix remodeling and migratory
behavior. Dynamic changes in the (ECM) in the
metastatic tumors. Inclusive in this is the down
regulation of important chemoattractants of
innate immune cells
Comparison of progressive melanoma states and their highest weighted immunological relevant genes.
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immunological relevance (p-val, 0.05). Overall, the trends
with immunological grading of these expression profiles
indicated that the assignment of an immunological rele-
vance to genes could classify patient groups with varied
immunological signatures. The same analysis was applied
to 38 patients from (Bogunovic et al, 2009), and it
revealed a significant correlation of upregulated immuno-
logical signatures in patients with prolonged survival (p-
val, 0.0086) and a significant correlation of downregu-
lated gene with patients that died (p-val, 0.0074). This
was also the case in Jonsson et al, where each patient had
a unique profile of clinical annotations and immunologi-
cal gene expression levels (Additional file 7). Interest-
ingly, the authors reported positive correlation with
tumor infiltrating leukocytes (TILs) in those patients
with favorable survival. A summary of these trends with
patient clinical annotations and the immunological pro-
files for each patient is listed in Additional file 7.
Discussion
The overlap between cancer and immunity has become
increasingly well established in recent years. Epidemiolo-
gically, 15-20% of cancer deaths are associated to inflam-
matory conditions [26]. Furthermore, inflammation is a
predisposition to cancer, and polymorphisms in cytokine
genes are associated to cancer severity [27,28]. Although
there is compelling evidence that supports this overlap,
an understanding of the molecular mechanisms of what
constitutes tumor-immune relationships is far from com-
prehensive [2,29]. This problem is complicated further by
the uniqueness of the microenvironment of each tumor,
and the complex interplay between cancer cell immune
factors and immune cells infiltrating the tumor.
Gene expression profiling has the potential to provide
an improved understanding of these complex relation-
ships and address these challenges. Current approaches
to assess the immune component of expression profiles
are dependent upon the application of limited pre-
defined sets of immune genes or terms. Prerequisite to
the success of manual approaches is the challenge of
defining the complete set of immune genes. We have
demonstrated that this challenge has not been met. The
crux in overcoming this challenge lies in what may be
considered to be an immune relevant gene. One option
to find immune genes with a role in cancer development
is the use of expertly annotated databases [20,30-32].
Our approach improves on the limitations of manual
approaches by applying a novel automated procedure
that quantifies the immunological relevance for all
human genes in bits of information. This score can be
directly applied to and provide a more informative and
quantitative assessment of the tumor immune compo-
nent from the gene expression profile. The novel use of
information bits to quantify the immunological
component may be even further generalized, and applied
to any phenotype or any other entity having been
assigned symbols of written communication.
Having access to a ranked immunological relevance
score for all genes provided an opportunity for analysis
of the resulting interactome landscape for tumor immu-
nity. This provided interesting insights into the relation-
ships with levels of immune and cancer information of a
gene in the interactome, in light of the new paradigm of
network biology [23,33]. These observations in particu-
lar add to the debate of the importance of central posi-
tions held by cancer [34] and immune [35] genes in the
cellular interactome network. Although there is on aver-
age higher connectivity for immune and cancer genes in
those studies, we illustrated variation about the average,
with certain peak genes raising the average connectivity
in the interactome landscape.
Tissue specific expression analysis of the immunologi-
cal relevance score demonstrated that there is a detect-
able difference among different tissues in the expression
of immune genes. Tissue specific network analysis
demonstrated that immune genes have distinguishably
robust connections within a cells interactome. These
observations may be explained by the diverse properties
of various tissues to interplay with the immune system
in maintaining tissue homeostasis. The strategy of apply-
ing a computationally derived immunological score to
capture the heterogeneity of the immunological compo-
nent of normal tissues adds reason to its application as
an immunological meta-analysis to cancer transcrip-
tomes. Indeed, quantifying the immunological compo-
nent of expression studies linked to clinical annotations
can lead to informative insights into the immune pro-
files of patient groups. The necessity and timeliness of
applying such a comprehensive computational strategy
to tumor expression profiles is highlighted by the
increasing reports of immune cell infiltrates in tumor
microenvironments as predictors of prognosis and survi-
val in various cancers [4,5,7,36-41].
A proposition for an immunological grading of a tumor
based on immune infiltrates has recently been made [42],
which would require the expertise of highly trained pathol-
ogists. Recent studies in malignant melanoma advocate
stratification based on molecular signatures from expres-
sion profiling [5,18]. The computational approach
described here serves in the automatic identification of
ranked immunological signatures and their network of
interactions, which leads to a strategy of grading the immu-
nological component of the gene expression of a tumor.
Melanoma was chosen to be the cancer type to
demonstrate this strategy, because of the prominent
immunological properties of normal skin [43,44] and
the strong tendency of melanoma to metastasize [45].
Among the genes harboring some of the highest
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immunological relevance, and with expression differ-
ences in both primary and metastatic profiles compared
to normal skin, were the CD4 and CD8 genes. This indi-
cates that our strategy pinpoints possible recruitment of
the adaptive immune response at early points in the
progression of melanoma in these tumors, which is inter-
esting in the context of increasing evidence that adaptive
immunity influences the behavior of human tumors [36].
With respect to melanoma, this further coincides with
recent evidence in mice that the metastatic transition is
an early event, and that proliferation of disseminating
cells is mediated by the function of CD8+ T-cells [46].
Concerning clinical analysis of metastatic melanoma
patients, this approach classified the patient group that
had immune signatures of upregulated high immunologi-
cally relevant genes, and the proliferative-tumor group
with down downregulation of high immunologically rele-
vant genes. It was apparent from the clinical analysis that
patients had unique combinations of clinical annotations
with both up and downregulated genes with high immu-
nological scores. The distinctive immunological profiles
for each patient may reflect the uniqueness of the
immune component of each microenvironment and the
contradictory role immune genes play in regulating can-
cer development [47].
This strategy does not grade the directionality of these
paradoxical roles in the tumor immune response.
Rather, it identifies and grades the magnitude of the
immune component of the expression profiles. We pro-
pose, however, that improving this strategy to do so will
precipitate the characterization of detailed mechanisms
underlying tumor-immune surveillance, tolerance and
escape and facilitate identification of powerful prognos-
tic factors.
Conclusions
We have assigned a ranked immunological relevance
score to all human genes applying a novel computa-
tional approach that utilizes information theory applied
to the medical literature. This score was used to chart
immunological relevance against the landscape of pro-
tein interaction networks. We propose that this
approach can be applied to elucidate the phenotypical
component of any complex disease. In this study we
focus on tumor immunity and melanoma to demon-
strate the ability of this strategy to identify and grade
the magnitude of the immune component of patient
expression profiles. The capability to analyze tumor
transcriptional profiles on a genome-wide scale offers a
means to investigate the immunological mechanisms of
the complex tumor immune relationships. In so doing,
such an approach can classify melanoma patient groups
into varied immune profiles that correlate with survival
and other clinical phenotypes.
Methods
Defining the dictionary of terms for immune and
neoplasm relevance
By doing manual searches in the Gene Ontology (GO)
[48] and the Medical Subject Headings (MeSH) (http://
www.nlm.nih.gov/mesh/) resources and documenting
those terms deemed relevant for the context, we com-
piled a list of 1921 immune and 562 neoplasm context
terms. This resulted in a comprehensive term list from
structured vocabularies that define the contexts in our
analysis. The manual searches were implemented using
domain knowledge of immunity and cancer. Strict scru-
tiny of relevance to the context was applied before
acceptance of a term into the context term list. The
manual searches in MesH and GO produced a candidate
list of terms. Each candidate term was read and then
categorized as being relevant or not relevant for immu-
nity or cancer based on the expert knowledge of an
immunologist or cancer researcher, respectively. As the
purpose of this study was to quantify the size of the
immune component of tumor samples, a broad scope of
immune terms was accepted, each term has an associa-
tion of an immune function, process, cellular anatomy
or immune condition according to the scrutiny of the
immunologist. The complete list of chosen immune and
neoplasm terms is presented in Additional file 1.
Extraction of human genes, immune and neoplasm terms
from Medline
One of the important elements in the approach is to
identify literature co-citations of human genes and their
associated GO and MeSH terms by using an established
method in text mining [19]. Here is a brief summary of
this method with more detail in the referenced article.
All official symbols, names and alias symbols for human
genes compiled from the Human Genome Organization
(HUGO) (http://www.genenames.org/), OMIM (http://
www.ncbi.nlm.nih.gov/omim/), and EntrezGene (http://
www.ncbi.nlm.nih.gov/gene), were automatically
extracted from all Medline article titles and abstracts.
The genes are indexed to PubMed IDs after a natural
language processing (NLP) step of the Medline abstracts
that involves procedures in part of speech tagging (POS)
and noun chunking, the purpose of which is to remove
false positives of biological term mentions. Some other
steps in obtaining the gene citation data of higher qual-
ity is to remove abbreviation type false positives, which
occur frequently because gene symbols often coincide
with other abbreviations having no connection or rele-
vancy with the gene symbol. Such data quality steps
yield a greater number unambiguous gene symbol cita-
tions in text with an improved precision. In a similar
manner to the extractions of gene from Medline text
GO terms are extracted using NLP techniques of POS
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and the GO terms mapped to their corresponding iden-
tifiers and indexed against noun chunks in Medline sen-
tences. MeSH terms are indexed to Medline abstracts by
using the National Library of Medicine’s (NLM) annota-
tions of MeSH terms to articles.
An immunological and cancer relevance score for all
human genes using information theory and text mining
The principle of Shannon’s entropy was first tested as a
sensible measure of information content applied to gene
associations derived from text mining. This was further
refined using the Kullback-Leibler (KL) score, thus cor-
recting for bias introduced by the popularity of the gene
to be co-cited in all of Medline which we found to
inherent in the Shannon entropy calculations.
In these information theory aproach we interpreted
gene co-citation events in medical articles with terms
from a lexicon of expertly chosen annotations from a
context as an information coding system for the context
(the context of immunity and cancer in this study). The
frequency of co-citation events of a manually annotated
context term i extracted from Medline abstracts using
text mining and co-cited with a human gene x is treated
as a message. This message is detected within each ele-
ment of an alphabet of symbols of size N, where N is
the total number of annotated terms in the lexicon of
that context. Immune and cancer experts manually
chose the elements of the alphabet of symbols N from
the structured biological vocabularies of GO and MeSH.
Thus we view the literature association between a gene
and a context term as the observance of a symbol
describing an element of that contextual message and
the probability of that event occurring is:
p(x) =
gi
iTg
gi is the number of co-citations for a gene with a con-
text term i in Medline and iTg is the total number of
times the context term i is cited with all human genes in
all of Medline (the total gene co-citation space of the
context term). Hence, the continuously expanding 20
million articles of Medline is the source emitting these
symbols with probabilities (p1, p2, . . ., pN) and these are
the symbols of communication that define an immunolo-
gical (or other contextual) score for all human genes. We
assume that the symbols are emitted independently for
each gene. In this assumption the probability that a gene
is associated to, for example, the immune term “T-cell
differentiation” in Medline is independent of its associa-
tion to the immune term “Macrophage” and their prob-
abilities are computed independently. These probabilities
of events (p1, p2, . . ., pN) give discrete values that can be
used to detect the size of a message and thus the
contextual information content for each gene as defined
by Shannon’s entropy [49]
Hc =
N∑
i
p(x)log2p(x)
Although the Shannon entropy provided the accurate
size of the information content for each gene, it did not
account for bias introduced by the popularity of the
gene Medline. We therefore refined the information the-
ory approach to correct for this bias. This bias was
defined as the popularity of the gene to be co-cited in
all of Medline, i.e. its probability of co-citation among
all GO and MeSH terms in the gene co-citation space
of Medline. We quantified this bias and corrected for it
using the Kullback-Leibler (KL or “relative entropy”) cal-
culation to create a more accurate measure of informa-
tion content that can be used as the immunological and
cancer score for each gene. The KL was used to deter-
mine the divergence of the observed probability p(x),
described above, from an assumed incorrect distribution,
which we take as the popularity of the gene in the total
Medline gene co-citation space q(x):
q(x) =
gT
GST
Where gT is the number of co-citations for a gene
with all GO and MeSH terms in Medline and GST is the
total number of co-citation events for all GO and MeSH
terms with all human genes in all of Medline (the total
gene co-citation space of GO and MeSH, the source of
the immune and cancer context terms chosen by
domain experts). This measures the expected amount of
information required to code a message from a context
term for a gene p(x) when using a code based on the
assumed incorrect probability q(x) rather than using a
code based on p(x) and is defined by Kulback-Leibler
KL as:
KL =
N∑
i
p(x)log2
p(x)
q(x)
As this relative entropy score (KL) corrects for the
bias q(x) for each gene, it was used as to calculate the
“immunological and cancer relevance” score throughout
this study.
Collating manually curated immune relevant gene sets
The immunology gene sets were compiled from the fol-
lowing manually curated sources: (1) Immport (https://
www.immport.org), (2) Immunome [20], (3) Iris [31], (4)
Mapk-Nfkb (ref), (5) Septic Shock (http://www.septic-
shock.org) and (6) InnateDB [30]. The HUGO (http://
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www.genenames.org/) symbol for genes provides a
unique identifier for human genes and is ideal for the
integration of text mining derived knowledge. It was
used in this study to integrate and determine the over-
lapping descriptive statistics for each of the six databases
and visualized in Venn diagrams in the VennMaster
software [50] to approximate their intersections by
incorporating the gene set size information. Similarly
genes from two efforts to catalogue the inflammatory
response [21,22] were integrated using their HUGO
gene symbols and compared to the unified immune
gene set from the above six different sources mentioned
above.
Constructing a validated human interactome & network
analysis
We constructed a human gene network by integrating
binary human interactions from IntAct [51], BioGRID
[51] and HPRD [52]. Each of these datasets of binary
interacting protein pairs was downloaded from their
source and the unique ids of the interactors were cross-
referenced to their NCBI gene IDs and official Gene
Symbols. This resulted in a unified set of binary NCBI
gene ID interactor pairs, with their corresponding offi-
cial gene symbols. The interaction data was limited to
these sources as they consist of validated protein-protein
interactions with experimental evidence curated from
critical reading of the scientific literature by expert
biologists.
This integrated data set is represented as an undir-
ected, unweighted network, where G = (V,E) comprising
of a set of nodes V and edges E. Each node represents a
human gene and each edge represents a pair of genes
(u,v) as a representation of a binary interaction in the
human interactome. If there exists a physical binary
interaction between u and v, in at least one of the pro-
tein products of each gene, an edge is connected. The
tissue specific interactomes were derived from the
entries in the three protein interaction databases men-
tioned above and the tissue expression annotations from
in a recent study integrating tissue specific interactions
from 79 human tissues [25].
Network centrality analysis was carried out on the
networks by means of calculating five measures of cen-
trality for each gene in the interactome (Connectivity,
betweeness, eccentricity, closeness and eigenvector). A
descriptions of equations implemented for these mea-
sures and full details of their context to protein net-
works in cancer are summarized here [53]
Microarray gene expression analysis and a composite
expression and immunological relevance score
Tissue specific gene expression data from the Symatlas
project [24] was analyzed to detect pairwise differential
expression across the 79 specific tissues [25] (Additional
file 8). We considered a gene differentially expressed
between any pair of tissues and therefore viable for
further analysis if there was greater than a two times
fold-change in expression. The average immunological
score was then determined for these differentially
expressed genes across all tissue pairs. A similar
approach was used for profiles in the progressive states
of skin cancer. For the gene expression profile linked to
patient survival probes [18] strict criteria were applied to
reduce false positive signals in that only those probes
with detection p-value < 0.01 in more than 50 out of the
total 57 patients were used. The software used to calcu-
late the detection p-values (Illumina BeadStudio) uses a
nonparametric method for the computation of detection
p-values. In this method the z-values of the probe signals
are ranked relative to the z-values of the negative control
signals. These were quantile normalized [54], and log2
transformed. Each probe signal intensity measurement
(S) was given a fold change relative to that probes mean
signal intensity (MSI) across all patients (P) and utilized
to create a weighed composite signal intensity and immu-
nological score for each gene (Wg):
P∑
1
log2(
S
MSI
).KL
The weighted expression and immune score for each
gene was then summated across all genes (M) for each
patient to generated a weighted immune score for each
patient (Wp):
M∑
1
Wg
The patient scores where compared to the clinical
annotations to find correlations between the weighted
immunological score (Wp) and the clinical phenotypes.
Monte Carlo simulations with 10,000 draws were used
to create a null distribution for each comparison. For
numerical phenotypes Pearson’s correlation were used.
Additional material
Additional file 1: Tables of manually curated immune and neoplasia
terms. These are the terms used to define the dictionary of terms for
immune and neoplasm context. Manually selected from GO and MeSH
using domain knowledge.
Additional file 2: Genome-wide ranked Immunological and
neoplasia relevance score for genes. Table depicting the
immunological and cancer relevance score for all human genes
quantified in bits using information theory calculation with Kullback-
Leibler adjustments
Additional file 3: Immunological relevance of non-curated genes.
Ranked immunological relevance of genes not populated in the
manually curated immune gene resources
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Additional file 4: Relationship of both immunological and cancer
relevance to network centrality. Tables reporting the Pearson
correlation coefficients of immunological and cancer relevance to the
principle network centrality measures of the human interactome.
Additional file 5: Tumor immunity interactome landscape. The
underlying data behind Figure 3, quantifying in bits of information the
immunological and cancer relevance charted against connectivity in the
interacome
Additional file 6: Table of the k-means classification by means of
the eccentricity centrality measure, showing biologically
meaningful classes of tissues. K-means classification of tissue groups
shown in Figure 5 (parameter K = 9). Determined by means of the
eccentricity centrality measure for each of the tissue specific
interactomes from the SymAtlas [24].
Additional file 7: Bogunovic et al, 2009 distinct patient profiles and
relationship to clinical phenotypes. Composite expression and
immunological relevance score for all genes in each patient in this study.
Demonstrated here as an example to offer an overview of the diversity
and uniqueness of the immunological profile, detected by this approach
in each individual patient samples.
Additional file 8: Normal tissue index. Index for the 79 normal tissues
from the SymAtlas [24] depicted in the heatmap of immunological
comparisons in Figure 4A
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